



(51) International Patent Classification:  
A61F 2/24 (2006.01)

(21) International Application Number:  
PCT/SG2017/050296

(22) International Filing Date:  
12 June 2017 (12.06.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10201604791X 13 June 2016 (13.06.2016) SG

(71) Applicant: SINGAPORE HEALTH SERVICES PTE.  
LTD. [SG/SG]; 31, Third Hospital Avenue, #03-03, Singa-  
pore 168753 (SG).

(72) Inventors: YEO, Khung Keong; c/o National Heart Cen-  
tre Of Singapore PTE. LTD., 31 Third Hospital Avenue,  
#03-03, Singapore 168753 (SG). FOIN, Nicolas Daniel  
Marie; c/o National Heart Centre Of Singapore PTE. LTD.,  
31 Third Hospital Avenue, #03-03, Singapore 168753 (SG).

(74) Agent: YUSARN AUDREY; 24 Raffles Place, #27-01  
Clifford Centre, Singapore 048621 (SG).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

**Published:**

- with international search report (Art. 21(3))

(54) Title: DEVICE FOR CARDIAC VALVE REPAIR AND METHOD OF IMPLANTING THE SAME




Figure 5B

(57) Abstract: The present invention relates to a device for cardiac valve repair, the device comprising: at least one upstream anchoring means adapted to anchor to at least one tissue site, the tissue site located upstream with respect to a heart valve of a patient; and a coaptation structure arranged to extend from the upstream anchoring means, the coaptation structure comprising a free end, wherein the coaptation structure is operable to extend across the heart valve and locate the free end downstream from the heart valve and the coaptation structure operable to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood. The present invention is suitable for the treatment of heart valves using minimally invasive approaches. Additionally, the present invention is directed to a method of implanting a device for cardiac valve repair in a patient's heart.

## DEVICE FOR CARDIAC VALVE REPAIR AND METHOD OF IMPLANTING THE SAME

### FIELD OF INVENTION

- 5 The invention relates to the field of implantable medical devices, in particular to cardiac valve repair devices and methods of implanting the same. The invention is suitable for transcatheter and minimally invasive heart valve treatment, in particular for repair of a non-functional tricuspid or mitral heart valve.

### 10 BACKGROUND OF INVENTION

#### Rationale

- Tricuspid regurgitation (TR) affects millions of people worldwide. It is difficult to treat and even surgical repair can fail. Some studies have shown long term moderate to severe recurrent TR of up to 30% in patients who receive surgical repair<sup>1</sup>. TR can result in significant complications
- 15 such as pulmonary hypertension, right heart failure, liver cirrhosis and the complications associated with right heart failure (eg. venous ulcers). Current treatment is largely medical with the use of diuretics such as Lasix and spironolactone. There has been no randomized trial showing the superiority of one treatment option over another.
- 20 The problem with TR is that it is seldom isolated. It often occurs together with other valvular heart disease or in the presence of heart failure or pulmonary hypertension. If surgery is performed for the primary valve disease, the tricuspid valve may be repaired or replaced at the same time. However, for many patients, the development of severe TR is a late manifestation and even when the primary pathology is treated, the TR can remain a problem.
- 25 This is because the right ventricle (RV) and the tricuspid annulus remodels and this seldom reverses. In other instances, the underlying pathology cannot be reversed, e.g. primary pulmonary hypertension or ischemic cardiomyopathy, but the secondary TR itself is a cause of significant morbidity and frequent hospitalization.

#### 30 Clinical need and current treatment limitations

- The current treatment for TR is either medical therapy or surgery. However surgery is of limited efficacy and significant risk. Recurrence after concomitantly performed with Mitral Valve (MV) surgery: 15% at 1 month, 31% at 8 years<sup>2</sup>; also dependent on repair technique e.g., ring annuloplasty 17%, Bicuspidization 14%<sup>2,3</sup>. There are current no working percutaneous models
- 35 of TR repair or Tricuspid Valve (TV) replacement although it is believed that a few companies and investigators have started work in the area. Clinical studies in patients are still lacking. Current approaches aim to replace the function of the tricuspid valve by implanting a stented valve as replacement of the native valve or by implanting stented valve in the inferior vena cava and the superior vena cava. By doing so, this last method aims to obviate the problem
- 40 of tricuspid regurgitation by removing the function of the right atrium. The current approaches are difficult in practice because of the large variation in tricuspid valve and vena cava anatomies. In addition, the vena cava approach is limited by the non-physiologic re-

arrangement of human anatomy and does not take into account effects of high right-sided cardiac pressures, which may continue its deleterious effects on the lungs.

The prevalence of isolated TR is poorly defined but approximates 0.8% to 3.8%<sup>4,5</sup>. Its effects are more commonly seen in patients with underlying left sided valvular heart disease such as in mitral stenosis or mitral regurgitation, ranging from 37 to 74%<sup>6-8</sup>. The clinical burden of TR is clear with right-sided heart failure refractory to treatment. Patients are prone to recurrent admissions. Other than symptomatic relief, there is no drug-therapy that has been shown in randomized trials to improve long-term prognosis.

It is one objective of the present invention to provide a minimally invasive and simple approach to treat valve regurgitation and avoid limitations associated with predicate minimally invasive heart valve treatment approaches. It is another objective of the proposed present invention to be implanted without general anaesthesia and/or open heart surgery.

It is a further objective of the present invention to avoid the disadvantages associated with complete heart valve replacement devices which cannot accommodate suitably for different valve annulus sizes and may require a complex delivery systems for implantation. The proposed device according to the present invention is designed with an objective of accommodating for various valvular anatomies and diseases.

#### SUMMARY OF THE INVENTION

The present invention seeks to address and/or ameliorate the problems in the prior art by providing a device for cardiac valve repair that is simple, capable of accommodating different valvular anatomies and diseases and is suitable for minimally invasive implantation approaches.

According to an aspect of the present invention, there is provided a device for cardiac valve repair, the device comprising: at least one upstream anchoring means adapted to anchor to at least one tissue site, the tissue site located upstream with respect to a heart valve of a patient; and a coaptation structure arranged to extend from the upstream anchoring means, the coaptation structure comprising a free end, wherein the coaptation structure is operable to extend across the heart valve and locate the free end downstream from the heart valve and the coaptation structure operable to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood.

The fact that the coaptation structure that is operable to extend across a heart valve to locate the free end of the coaptation structure downstream from the heart valve, allows the coaptation structure to, without hindrance and restriction (e.g. via a downstream anchor), effectively replace and/or support the coaptation function of a failing valve leaflet, and/or to act as an additional support for coaptation of the valve leaflets which are spaced further apart due to for example, annular dilatation. Locating the free end of the coaptation structure downstream from

the heart valve allows for optimal efficiency in the coaptation of the coaptation structure and the valve leaflets.

Preferably, the coaptation structure is flexible.

5

Preferably, the coaptation structure comprises a balloon having a surface for coaptation of at least one heart valve leaflet of the patient's heart. More preferably, the balloon is expandable.

10

Preferably, the device further comprises a connecting means adapted to connect the upstream anchoring means and the balloon, wherein the connecting means is adapted to arrange the balloon at a first location between two or more heart valve leaflets of the patient's heart.

15

Preferably, the coaptation structure comprises a neo-leaflet. More preferably, the neo-leaflet comprises a means for providing structure to the neo-leaflet and wherein said means is flexible. Even more preferably, the neo-leaflet comprises a polymer, fabric, tissue or combination thereof. Preferably, the neo-leaflet is expandable.

20

Preferably, the device further comprises a connecting means adapted to connect the upstream anchoring means and the neo-leaflet, wherein the connecting means is adapted to arrange a portion of the neo-leaflet at a first location between two or more heart valve leaflets of the patient's heart.

25

Preferably, the neo-leaflet is extendable onto a surface of at least one heart valve leaflet of the patient's heart.

Preferably, at least a portion of the neo-leaflet is extendable into a commissure between two adjacent heart valve leaflets of the patient's heart.

30

Preferably, the device comprises a stabilizing structure adapted to extend across the heart valve of the patient, and wherein the stabilizing structure is configured to maintain the downstream location of the free end of neo-leaflet. More preferably, the stabilizing structure comprises a weighted free end.

35

Preferably, the stabilizing structure comprises one or more stabilizing tether adapted to connect the stabilizing structure to the neo-leaflet. More preferably, the stabilizing tether is adapted to connect to the free end of the neo-leaflet.

40

Preferably, the coaptation structure comprises a membrane, wherein a portion of the membrane is extendable into a commissure between two adjacent heart valve leaflets of the patient's heart.

Preferably, the upstream tissue site is a blood vessel and the upstream anchoring means is a stent.

Preferably, the heart valve is a tricuspid valve. More preferably, the stent is adapted to anchor at the coronary sinus of the patient's heart, and/or the stent is adapted to anchor at the inferior vena cava of the patient.

5

Preferably, the device comprises a second upstream anchoring means, wherein the second upstream anchoring means is a stent adapted to anchor at the superior vena cava of the patient.

10 Preferably, the heart valve is a mitral valve and the stent is adapted to anchor at a pulmonary vein of the patient's heart.

Preferably, the upstream anchoring means and the coaptation structure are separate components of the cardiac valve repair device and wherein the upstream anchoring means and the coaptation structure are configured to connect with one another, or optionally, the upstream anchoring means and the coaptation structure are a unitary structure.

15

Preferably, the device is crimpable or compressible for transcatheter delivery.

20 According to another aspect of the present invention, there is provided a method of implanting a device for cardiac valve repair in a patient's heart, the method comprising the steps of:

- a) delivering a device for cardiac valve repair to the patient's heart, the device comprising at least one upstream anchoring means and a coaptation structure arranged to extend from the upstream anchoring means;
- 25 b) anchoring the upstream anchoring means to at least one tissue site in the patient's heart, the tissue site located upstream with respect to a heart valve of the patient's heart;
- c) deploying the coaptation structure to extend across the heart valve to locate a free end of the coaptation structure downstream from the heart valve, and for the coaptation structure to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood.

30

Preferably, the upstream anchoring means and the coaptation structure are separate components and the method comprises delivering the upstream anchoring means and the coaptation structure separately to the patient's heart. More preferably, the method further comprises the step of connecting the upstream anchoring means with the coaptation structure. Even more preferably, the upstream anchoring means and the coaptation structure are connected via a connecting means.

35

40 Preferably, the method further comprises the step of testing and verifying the stability of the upstream anchoring means.

Preferably, the method comprises deploying the coaptation structure before anchoring the upstream anchoring means.

5 Preferably, the coaptation structure is expandable and the method further comprises the step of expanding the coaptation structure.

10 Preferably, the upstream anchoring means is a stent and the method comprises anchoring the stent at the coronary sinus of the right atrium of the patient's heart, and deploying the coaptation structure such that the free end of the coaptation structure extends into the right heart ventricle of the patient and the coaptation structure coapts with at least one tricuspid valve leaflet of the patient's heart.

15 Preferably, the upstream anchoring means is a stent and the method comprises anchoring the stent at the inferior vena cava of the patient, and deploying the coaptation structure such that the free end of the coaptation structure extends into the right heart ventricle of the patient and the coaptation structure coapts with at least one tricuspid valve leaflet of the patient's heart.

20 Preferably, the cardiac valve repair device comprises a second upstream anchoring means, wherein the second upstream anchoring means is a second stent and the method comprises anchoring the second stent at the superior vena cava of the patient.

25 Preferably, the upstream anchoring means is a stent and the method comprises anchoring the stent at a pulmonary vein of the left atrium of the patient's heart, and deploying the coaptation structure such that the free end of the coaptation structure extends into the left heart ventricle of the patient and the coaptation structure coapts with at least one mitral valve leaflet of the patient's heart.

30 Preferably, the delivery of the cardiac valve repair device is via transcatheter delivery. More preferably, the delivery of the cardiac valve repair device is under fluoroscopic or ultrasound imaging guidance.

Preferably, the coaptation structure comprises a neo-leaflet.

35 According to another aspect of the present invention, there is a device for cardiac valve repair, the device comprising: a first upstream anchoring means adapted to anchor to a first tissue site in a patient's heart; a second upstream anchoring means adapted to engage a second tissue site in the patient's heart; and a flexible backflow barrier arranged between, and extending from the first and second upstream anchoring means, wherein the first and second tissues site are located upstream with respect to a heart valve of the patient and the backflow barrier is arranged close to the heart valve of the patient to prevent and/or minimize backflow of blood.

40

Preferably, the backflow barrier is substantially planar. Preferably, the backflow barrier comprises a neo-leaflet having a flexible frame. More preferably, the neo-leaflet comprises a polymer, fabric, tissue or combination thereof.

- 5 Preferably, the first upstream anchoring means is adapted to anchor at the coronary sinus of the patient's heart and the second upstream anchoring means is adapted to abut against a portion of the right arterial wall of the patient's heart.

- 10 Preferably, the first upstream anchoring means is adapted to anchor at the pulmonary vein of the patient's heart and the second upstream anchoring means is adapted to abut against a portion of the left arterial wall of the patient's heart.

- 15 According to another aspect of the present invention, there is a device for cardiac valve repair, the device comprising: an upstream anchoring means adapted to anchor to an upstream tissue site, the upstream tissue site located upstream with respect to a heart valve of a patient; and a neo-leaflet arranged to extend from the upstream anchoring means, wherein the neo-leaflet is operable to extend across the heart valve and the coaptation structure is operable to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood.

- 20 Preferably, the device comprises a downstream anchoring means configured to extend from an end of the neo-leaflet, and wherein the downstream anchoring means is adapted to anchor at a downstream tissue site with respect to the heart valve of the patient.

- 25 Preferably, the downstream tissue site is an endocardial or pericardial tissue site of a heart ventricle of the patient.

- 30 Preferably, the upstream anchoring means is adapted to anchor at the coronary sinus of the patient's heart or optionally, the upstream anchoring means is adapted to anchor to a pulmonary vein of the patient's heart.

#### BRIEF DESCRIPTION OF THE DRAWINGS

- 35 The present invention will now be described, by way of example only, with reference to the accompanying drawings, which are for illustrative purposes only and are therefore not drawn to scale, in which:

Figure 1A is a schematic axial sectional view of a heart showing the anatomical relationship between the coronary sinus and the tricuspid valve.

- 40 Figure 1B is a perspective view of a 3D reconstruction of the heart section of Figure 1A.

Figure 2 is a schematic coronal view of the heart of Figure 1 showing the anatomical relationship between the coronary sinus and the tricuspid valve. The coronary sinus is medial

and superior to the tricuspid valve, generally above the posterior-septal commissure, although some variability in the position and height may exist.

Figure 3 is a schematic coronal section of the right heart atrium RA and ventricle RV with the cardiac valve repair device according to an embodiment of the present invention. The device 10 comprises a stent 11 anchored in the coronary sinus 6 and a deployable coaptation structure 12 extending into the right ventricle RV, functioning as a one-way valve repair.

Figure 4 is a schematic axial sectional view of the cardiac valve repair device according to an embodiment of the present invention as shown in figure 3, with the deployable coaptation structure 12 shaped as a neo-leaflet extending into the right ventricle.

Figure 5A is a schematic side profile drawing of a cardiac valve repair device according an embodiment of the present invention, with a stent 11 and a deployable coaptation structure 12 extending from the inferior border 11a of the stent 11.

Figure 5B is a schematic top down view of the device of Figure 5A with a stent 11 and a deployable coaptation structure 12 extending from the inferior border 11a of the stent 11.

Figures 5C is a schematic en-face view of a device of Figure 5A and 5B with a stent 11 and a deployable coaptation structure 12 extending from the inferior border 11a of the stent 11.

Figure 6 is a schematic view of a cardiac valve repair device according to an embodiment of the present invention, with a deployable coaptation structure 112 connected to the stent 111 by tethers 113.

Figure 7 is a schematic view of a cardiac valve repair device according to an embodiment of the present invention, with a stent 211 implanted in a coronary sinus 6 above the valve 2 and a coaptation structure 212 with an expanded portion 214 located in the middle of the valve 2 providing a support for the coaptation of a heart valve leaflet.

Figure 8 is a schematic coronal view of a left side of the heart with an implanted device according to the embodiment as shown in Figures 5A to 5C. The device comprises an anchoring stent 11 implanted in a pulmonary vein 7 above the mitral valve 3, with a coaptation structure 12 extending in between the mitral valve leaflets.

Figure 9A is a schematic axial view of the heart with a different embodiment of a device (1) with an anchoring stent (2) and with a deployable valve repair structure shaped as a membrane wall structure extending between the leaflets (31), here between the septal and posterior leaflets.

Figure 9B is a schematic coronal section view of a left heart atrium and ventricle with an implanted cardiac valve repair device as shown in Figure 9A. The device comprises a stent



311 deployed in the ostium 6a of blood vessel 6 (coronary sinus) located above the valve 2 and a deployable coaptation structure 312 extending between at least two of the valve leaflets 2b, 2c and functioning as a septum enhancing coaptation of the valve leaflets.

- 5 Figure 10A is a schematic axial sectional view of a heart with a cardiac valve repair device according to an embodiment of the present invention, with a deployable backflow barrier 412 having two legs 415 extending between and superior to the leaflets of the tricuspid valve 2.

10 Figure 10B is a schematic coronal section view of a right heart ventricle with the cardiac valve repair device as shown in figure 10A. The device includes a stent 411 deployed in the coronary sinus 6 located above the valve 2 and a backflow barrier 412 deployed in the right atrium above the valve leaflets and with legs 415 extending to the opposite side/wall of the right atrium.

- 15 Figure 11 is a schematic coronal sectional view of a right heart ventricle with a cardiac valve repair device according to an embodiment of the present invention. The device comprises a stent 511 deployed in a vessel located above the valve 2, a deployable coaptation structure 512 extending into the right ventricle RV and a downstream anchoring means 516 at the end of the coaptation structure 512.

20 Figure 12A is a schematic coronal view of a heart with an implanted cardiac valve repair device according to an embodiment of the present invention, where the device comprises a stent 611 anchored to the inferior vena cava 9 and a deployable coaptation structure 612 from the stent 611 into the right ventricle RV.

- 25 Figure 12B is a schematic axial sectional view of the heart of Figure 12A along axis A-A'.

30 Figure 13 is a schematic coronal view of a heart with an implanted cardiac valve repair device according to an embodiment of the present invention, where the device comprises a stent 711 anchored to the inferior vena cava 9, a deployable coaptation structure 712 from the stent 711 into the right ventricle RV and a downstream anchoring means 716 at the end of the coaptation structure 712.

- 35 Figure 14 is a schematic perspective view of a cardiac valve repair device according to the embodiment of Figures 5A to 5C.

40 Figure 15 is a perspective and enlarged view of a 3D reconstruction of a cardiac valve repair device according the embodiment of Figures 5A to 5C, implanted in the right atrium of a heart, where the stent 11 is anchored at the coronary sinus 6, and the coaptation structure 12 extends into the right ventricle via the tricuspid valve.

Figure 16A is a perspective view of a 3D reconstruction of an implanted cardiac valve repair device according to an embodiment of the present invention. The device comprises a stent

811 anchored at the coronary sinus 6 with a coaptation structure 812 extending into the right ventricle RV. The device also comprises a stabilizing structure 817 connected to the coaptation structure 812 via stabilizing tethers 818.

5 Figure 16B is a perspective view of the device of Figure 16A, viewed from the right ventricle.

Figures 17A to 17F illustrate steps of a method for delivering, deploying and implanting a cardiac valve repair device according to an embodiment of the present invention, where a stent 11 is implanted in the coronary sinus of a right heart atrium and a coaptation structure  
10 12 extends across a tricuspid valve, from the stent 11.

Figures 18A to 18D illustrate steps of a method for delivering, deploying and implanting a cardiac valve repair device according to another embodiment of the present invention, where a stent 611 is implanted in an inferior vena cava and a coaptation structure 612 extends across  
15 a tricuspid valve, from the stent 611.

Figures 19A to 19D illustrate steps of another method for delivering, deploying and implanting a cardiac valve repair device according to the embodiment of the present invention according to Figures 18A to 18D, where a stent 611 is implanted in an inferior vena cava and a coaptation  
20 structure 612 extends across a tricuspid valve, from the stent 611.

#### DETAILED DESCRIPTION OF THE INVENTION

Particular embodiments of the present invention will now be described with reference to the accompanying drawings. The terminology used herein is for the purpose of describing  
25 particular embodiments only and is not intended to limit the scope of the present invention. Other definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout the description. Additionally, unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Where possible,  
30 the same reference numerals are used throughout the figures for clarity and consistency.

Throughout the specification, unless the context requires otherwise, the word “comprise” or variations such as “comprises” or “comprising, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of  
35 integers.

Furthermore, throughout the specification, unless the context requires otherwise, the word “include” or variations such as “includes” or “including” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of  
40 integers.

Throughout the specification, a "patient" includes human and animal patients. Accordingly, the cardiac valve repair device of the present invention is suitable for use in human hearts and animal hearts.

5 Medical terms, terminology and references used throughout the specification will have ordinary meaning in the medical field and will be understood by a skilled person in said field. Such terms, terminology and references include but are not limited to "coapt", "superior", "inferior", "posterior", "anterior", "proximal", "distal", "septal", "atrium", "ventricle" and "vena cava". Anatomical terms and references are based on the standard anatomical position of the  
10 patient, for example for humans, the anatomical position is a human standing erect, with feet facing forward, the arms at the sides, palms of the hands facing forward with thumbs pointing away from the body and fingers pointing straight down. Therefore throughout the specification and as depicted in the figures, the atrial end of a heart is considered above the ventricular end of the heart when the patient is in an anatomical position. In particular, the atrium is considered  
15 upstream from the ventricle of a heart, where blood normally flows from the atrium to the ventricle.

Throughout the specification, the terms "upstream" and "downstream" are taken with reference to a heart valve being treated/repair, and with respect to the normal flow of blood. For example,  
20 the right atrium RA is considered upstream to the right ventricle RV, since the right atrium RA is before the tricuspid valve and since blood normally flows from the right atrium RA to the right ventricle RV. Further, the right ventricle RV is considered upstream to the pulmonary artery, since the right ventricle RV is before the pulmonary valve and since blood normally flows from the right ventricle RV to the pulmonary artery. As an additional example and with  
25 reference to Figures 16A and 16B, the stent 811 is located at an upstream location with respect to the tricuspid valve 2 and the weighted end 816a is located at a downstream location with respect to the tricuspid valve 2.

Figures 1A, 1B and 2 provide different views of the heart and its chambers. In particular, Figure  
30 2 shows the anatomical relationship between the coronary sinus 6 and the tricuspid valve 2. A heart 1 comprises a right atrium RA, right ventricle RV, left atrium LA and left ventricle LV. The right atrium RA and left atrium LA are respectively separated from the right ventricle RV and left ventricle LV by the tricuspid valve 2 and mitral valve 3 (collectively known as the atrioventricular valves). The mitral valve 3 is also known as a bicuspid valve. Further, the  
35 pulmonary artery (not shown) is separated from the right ventricle LV by the pulmonary valve 5 while the aorta (not shown) is separated from the right ventricle RV by the aortic valve 4. The coronary sinus 6 is medial and superior to the tricuspid valve 2, generally above the posteroseptal commissure 2d, although some variability in the position and height may exist. The coronary sinus 6 is a collection of veins joined together to form a large vessel that collects  
40 deoxygenated blood from the heart muscle (myocardium), and delivers it to the right atrium RA.

The native atrioventricular valves comprise flexible leaflets that extend from an annulus inward towards one another, across the respective orifices. The leaflets come together or "coapt" in the flowstream to form the one-way fluid occluding surfaces. The leaflets come together at commissures, e.g. posteroseptal commissure 2d. Tricuspid valve 2 comprises anterior leaflet 2a, posterior leaflet 2b and septal leaflet 2c while mitral valve 3 comprises anterior leaflet 3a and posterior leaflet 3b. The heart 1 also comprises chordae tendineae (not shown) which are cord-like tendons in the ventricles and which connect the papillary muscles to the tricuspid and mitral valve leaflets. The chordae tendineae prevent the eversion and prolapse of the leaflets, especially during systole, by becoming tense and pulling the leaflets, holding them in closed positions.

The right atrium RA receives deoxygenated blood from the venous system through the superior vena cava 8 and the inferior vena cava 9, while the left atrium LA receives oxygenated blood from the lungs through the pulmonary veins 7. During ventricular diastole, blood in the atria is pumped through the tricuspid valve 2 and mitral valve 3 into the ventricles, by contraction of the atria muscles and expansion (relaxation) of the ventricular muscles. During ventricular systole, the right ventricle RV contracts and pumps blood to the lungs via the pulmonary artery while the left ventricle LV contracts and pumps blood to the rest of the body via the aorta. During ventricular systole, the leaflets of the tricuspid valve 2 and mitral valve 3 close to prevent the blood from regurgitating back from the ventricles into the atria.

The present disclosure provides exemplary embodiments directed to cardiac valve repair devices and methods of implanting the same, for improving the function of a heart valve. Throughout the specification, a heart valve includes native and prosthetic/artificial heart valves. Therefore the cardiac valve repair device of the present invention is adapted to treat and/or repair native and prosthetic/artificial heart valves. Further, a heart valve includes the tricuspid valve, mitral (bicuspid) valve, pulmonary valve and the aortic valve.

Individual components of the disclosed devices may be combined unless mutually exclusive or otherwise physically impossible. Various embodiments of anchoring means, connecting means and coaptation structures are disclosed herein, and any combination of such elements may be made unless specifically excluded. For example, any of the coaptation structures may be combined with any anchoring means which includes but are not limited to stents and clamps, even if not explicitly disclosed. Likewise, the different constructions of coaptation structures may be mixed, matched and/or combined, such as combining any tissue cover with a flexible frame, even if not explicitly disclosed.

The present invention relates to a cardiac valve repair device and a method of treating heart valve regurgitation using minimally invasive approaches, where the cardiac valve repair device aims to prevent, reduce and/or minimize regurgitation of blood flow across a diseased and/or failing heart valve, or a failing prosthetic valve. The present invention also relates to a method of implanting the cardiac valve repair device. Further, the present invention relates to a new

method of repairing or replacing the tricuspid valve. Additionally, the present invention is also directed to a method of delivering and producing such device.

The present invention relates to the repair or treatment of diseased heart valves or failing  
5 prosthetic heart valves using a minimally invasive or transcatheter implantable cardiac valve  
repair device. The present invention relates to a method of treating heart valve regurgitation  
using minimally invasive approaches and a device which aims to prevent, reduce and/or  
minimize regurgitation of blood flow across the diseased and/or failing valve or failing  
10 prosthetic valve. Native valves may lose their ability to close properly due to several reasons  
which include but are not limited to dilation of an annulus around the valve, ventricular dilation,  
or a valve leaflet being flaccid causing a prolapsing leaflet. Disease (e.g. rheumatic disease)  
may cause valve leaflet shrinkage, thereby leaving a gap in the valve between the valve  
leaflets. Prosthetic heart valves can fail from for example wear and tear, fatigue and cavitation.  
15 Regurgitation is therefore a leak backwards (i.e., from the outflow to the inflow side, or from  
downstream to upstream) of blood resulting from the inability of the heart valve to close  
properly. Heart valve regurgitation may seriously impair the function of the heart since more  
blood will have to be pumped through the regurgitating valve to maintain adequate circulation.

The present invention is intended to treat and repair the atrioventricular and semilunar valves,  
20 and in particular the tricuspid valve. Therefore, anatomical structures of the right atrium RA  
and right ventricle RV will be explained in greater detail in the specification herein, although it  
should be understood that the present invention may equally be used to treat or repair the  
mitral valve, the pulmonary valve and the aortic valve.

#### 25 Cardiac Valve Repair Device

In various embodiments, the cardiac valve repair device of the present invention comprises at  
least one upstream anchoring means implantable above a diseased/failing valve and a  
coaptation structure extending into the disease valve annulus as a means to restore function  
of the said diseased valve. The upstream anchoring means is preferably anchored (i.e.  
30 implanted) at a tissue site located upstream with respect to the diseased/failing valve, for  
example in the atrial wall.

The cardiac valve repair device of the present invention is preferably a catheter-delivered  
device that can be percutaneously delivered for example via the venous system to the right  
35 side of the heart, although implantation of the device of the present invention may be done by  
for example open heart surgery. Percutaneous delivery can also be conducted via the  
intercostal or subxyphoid space, or an endoscopic catheter-based antegrade, retrograde, or  
trans-septal deployment, such methods as known in the art. The entire catheter-delivery  
device may then comprise of:

- 40 1. A delivery catheter;
2. An anchoring means (upstream anchoring means); and
3. A deployable valve repair (coaptation) structure which aims to restore the  
diseased/failing valve function.

The upstream anchoring means and the deployable coaptation structure may be implanted and deployed separately, as a single entity or some combination thereof. The deployable coaptation structure may be attachable to the anchoring means via a connecting means, which includes but is not limited to tethers. The deployable coaptation structure and the upstream anchoring means can be crimped/compressed to fit within the delivery catheter and ejected, e.g. by an obturator, from the delivery catheter to the target location, for example the upstream anchoring means being anchored to the coronary sinus.

The upstream anchoring means includes but is not limited to stents, clamps, hooks, tines, barbs, screws, and bioadhesives. Where the upstream anchoring means is for example a clamp or hook, the upstream anchoring means is capable of piercing the intended tissue site for anchorage. Such upstream anchoring means can comprise tissue (natural or artificial/engineered), metal, metal alloy, polymer or other man-made material, or a combination thereof. One or more upstream anchoring means may be used to anchor and secure the device of the present invention to one or more upstream tissue sites. Where more than one upstream anchoring means is used, the type of upstream anchoring means may be different from one another. Preferably, the upstream anchoring means is a stent. The upstream anchoring means is preferably bio-inert and/or biocompatible.

Examples of bioadhesives referred in the specification herein, include but are not limited to synthetic polymer glues such as epoxy resins, epoxy putty, ethylene-vinyl acetate, phenol formaldehyde resins, polyamides, polyester resins, polypropylene, polysulfides, polyurethane, polyvinyl acetate, polyvinyl alcohol, polyvinyl chloride, polyvinylpyrrolidone, silicones and styrene acrylic copolymer; synthetic monomer glues such as acrylonitrile, cyanoacrylate, acrylic and resorcinol glue; and solvent-type glues such as polystyrene cement/butanone and dichloromethane.

The coaptation structure includes but is not limited to balloons, flaps, leaflets and membranes. Preferably, the coaptation structure is flexible. Preferably, the coaptation structure is a neo-leaflet. In use, the coaptation structure coapts with at least one heart valve leaflet and/or provides a surface on which at least one heart valve leaflet can coapt against.

In various embodiments, the cardiac valve repair device may comprise a stabilizing means that maintains the location of an end of the coaptation structure in the ventricle.

In various embodiments, the device comprises one or more downstream anchoring means adapted to anchor the device to a tissue site, at a downstream location with respect to the heart valve. The downstream anchoring means may be an extension of the coaptation structure or the stabilizing means. The downstream anchoring means includes but is not limited to clamps, hooks, tines, barbs, screws and bio-adhesives. Where the downstream anchoring means is for example a clamp or hook, the downstream anchoring means is capable of piercing the intended tissue site for anchoring. Such downstream anchoring means can

comprise tissue (natural or artificial/engineered), metal, metal alloy, polymer or other man-made material, or a combination thereof. One or more downstream anchoring means may be used to anchor and secure the device of the present invention to one or more downstream tissue sites. Where more than one downstream anchoring means is used, the type of downstream anchoring means may be different from one another. The downstream anchoring means is preferably bio-inert and/or biocompatible.

The cardiac valve repair device may be manufactured out of a nitinol-titanium tube and manufactured by processes such as laser cutting, polishing and thermal molding in order to achieve a self-expandable implantable device comprising both an expanding stent structure and the frame of the coaptation structure. The device may also be manufactured wholly or partly from tissue (includes natural and artificial/engineered). Preferably, such tissue comprises or is capable of simulating one or more physiological functions.

#### Stents

Stents may be made of tissue, metal, metal alloy, polymer or other man-made material, or a combination thereof. Preferably, the stents of the present invention comprise elastic metals and/or metal alloys having shape memory, which includes but are not limited to nitinol-titanium (nitinol), Cu-Zn-Al-Ni alloys and Cu-Al-Ni alloys. Preferably the stent of the present invention comprises nitinol-titanium which allows the stent to be crimped/compressed and which allows the stent to return to its original, uncrimped/uncompressed shaped when released from for example, the delivery catheter. Nitinol-titanium can be processed to be austenitic, martensitic and/or super elastic. Martensitic and super elastic metals/metal alloys can be processed to demonstrate required compression/crimpable features.

Stents include laser cut stents or braided stents. In the manufacture of laser cut stents, a laser cuts regular cut-outs in a thin isodiametric metal/metal alloy tube. The tube is thereafter placed on a mold of the desired shape, heated to the Martensitic temperature and quenched. The treatment of the stent in this manner will form a stent that has shape memory properties and will readily revert to the memory shape at the calibrated temperature. Laser cut stents are preferably made from nitinol-titanium, but may also be made from for example stainless steel, cobalt chromium, titanium, and other functionally equivalent metals and alloys.

Braided stents are constructed using braiding techniques. A metal/metal alloy wire is wound on a braiding fixture/mandrel in an over and under braiding pattern until an isodiametric tube is formed from the wire. A coupling tube made of stainless steel or nitinol-titanium is then used to couple the loose ends of the wire. The loose ends are placed in the coupling tube and crimped. The braided stent is thereafter placed on a shaping fixture and heated to a specified temperature to set the stent to the desired shape and to develop the martensitic or super elastic properties desired.

The stent of the present invention may be made available in different sizes. Different diameter stent sizes may be provided in various embodiments of the device as the blood vessels (e.g.

coronary sinus) in which the stent is to be anchored can be highly variable in size. Multiple diameters and lengths can be made available. As the stent is preferably compressible/crimpable and expandable, the diametric size of the stent can be customized and configured to the blood vessel in which it anchors, for example a balloon catheter can be made to radially expand the stent such that the stents abuts and lodges into the tissue of a blood vessel so as to improve the anchorage and stability of the stent at the tissue site/blood vessel.

The stent of the present invention may be an expandable stent, and the expandable stent may be self-expanding or balloon expandable. Preferably, the stent is flexible.

The stent may comprise tines and barbs arranged along an outer surface that latch onto tissue, to improve anchorage and stability of the stent.

#### Coaptation Structure

Various coaptation structures may be used in the cardiac valve repair device of the present invention. The coaptation structure is shaped to extend across a patient's heart valve and position/locate one of its ends downstream with respect to the heart valve, for example, the coaptation structure is arranged to extend into a right heart ventricle across a tricuspid valve.

The coaptation structure preferably extends into the heart ventricle substantially via the centre of the heart valve annulus. In various embodiments, the coaptation structure or part thereof extends into the heart ventricle via the valve commissures, i.e. between adjacent valve leaflets.

The coaptation structure is constructed so as to provide sufficient structural integrity to withstand the intracardiac forces without collapsing. Choice of, shape and size of the coaptation structure depends on a physician's preference, which in turn depends on for example the patient's heart anatomy and condition. Importantly, the coaptation structure allows blood to flow from the atrium into the ventricle, without or with minimal regurgitation of flow, thereby restoring valve function.

The coaptation structure includes but is not limited to balloons, flaps, leaflets and membranes. Throughout the specification where the coaptation structure is a flap or leaflet, the coaptation structure will be referred to as a "neo-leaflet", to differentiate the coaptation structure of the present invention, from the native valve leaflets and/or prosthetic valve leaflets that the cardiac valve repair device is intended to treat, repair and/or replace.

Preferably, the coaptation structure is flexible.

The coaptation structure can be made from tissue, biocompatible and/or bio-inert materials or combinations thereof. Tissue includes but is not limited to biological animal tissue which may be chemically stabilized, for example bovine (cow) pericardium, ovine (sheep) pericardium, porcine (pig) pericardium or equine (horse) pericardium, and engineered tissue.



Biocompatible and/or bio-inert materials include but are not limited to metals, fabrics and polymers. Biocompatible polymers include but are not limited to polyurethane, polyethylene terephthalate (PET), polytetrafluoroethylene (PTFE), polyetheretherketone (PEEK),  
 5 polystyrene-b-polyisobutylene-b-polystyrene (SIBS), polyester, polycarbonate urethane, polycarbonate silicone, polyether urethane, segmented polyether urethane, silicone polyether urethane, silicone, polycarbonate urethane, ultrahigh molecular weight polyethylene, polyolefin, elastomers, nylon, polyethylene-glycols, polyethersulphones, polysulphones, polyvinylpyrrolidones, polyvinylchlorides, other fluoropolymers, silicone polyesters, siloxane  
 10 polymers and/or oligomers, polylactones and block co-polymers.

The coaptation structure or part thereof may be treated with additives, for example, immunosuppressants and anti-coagulants (such as heparin).

15 In various embodiments, the coaptation structure comprises a structural support frame which maintains the shape, size and flexibility of the coaptation structure. The structural support frame may be made from tissue (natural or artificial/engineered) metals, metal alloys, polymers, or a combination thereof. Preferably the structural support frame is made from elastic metals and/or metal alloys having shape memory, which includes but are not limited to  
 20 nitinol titanium (nitinol), Cu-Zn-Al-Ni alloys and Cu-Al-Ni alloys. More preferably, the structural support frame is made from nitinol-titanium.

In various embodiments, the coaptation structure is a balloon, where the structural support frame (for example comprising structural ribs) which provides the shape of the balloon, can  
 25 be covered by bioprosthetic tissues and/or biocompatible synthetic materials. The balloon may be in the form of a rounded structure, having a tubular, ovoid or near-spherical shape that can act as a supporting occluding element, which can be centrally located within the heart valve being repaired, to facilitate coaptation of the valve leaflets around the balloon to prevent flow regurgitation. In the particular cases of the mitral and tricuspid valves, the failing leaflets may  
 30 not be coapting thereby leaving a gap in the valve that causes the regurgitation of flow from the ventricle into the atrium during the systolic phase. The balloon as an occluding coaptation structure, acts as a support that restores the coaptation of the failing or prolapsing leaflet, thereby preventing flow from regurgitating from the ventricle back into the right atrium. The balloon provides a surface for coaptation of at least one heart valve leaflet.

35 The balloon can have various radial shape profiles and such shape profiles may vary along the length of the balloon, for example one end portion of the balloon may be circular while the other end is triangular. The balloon can have various sizes (i.e. radial diameter) and lengths. The size and length of the balloon can depend on for example, the size of the valve annulus and the length of the heart valve leaflets. The balloon is preferably shaped and sized to provide  
 40 an exterior surface for the valve leaflets to coapt against. Preferably, the exterior surface of the balloon is continuous.

In various embodiments, the balloon is self-expandable upon delivery or is capable of being inflated in a similar fashion as a balloon catheter, e.g. via an external access port.

5 In various embodiments, the coaptation structure is a neo-leaflet, where a wire (or a plurality of wires) is shaped to form the structural support frame for the neo-leaflet, and the bioprosthetic and/or biocompatible material covers the frame. The frame provides flexibility to the neo-leaflet, such that the neo-leaflet is capable of functioning in a substantially similar manner as natural heart valve leaflets. The neo-leaflet is capable of acting as an extension of a failing valve leaflet to restore valve coaptation and prevent leaflet prolapse. In various  
10 embodiments, the neo-leaflet may be formed from an animal tissue having an inherent structural frame such that the neo-leaflet does not require a separate structural support frame formed from a metal, metal alloy, polymer or a combination thereof.

15 The neo-leaflet can have various shapes and sizes, for example the shape of a tricuspid valve leaflet or part thereof. The shape and size of the neo-leaflet depends on for example the length of the heart valve leaflets. Further, the neo-leaflet can have different thickness along its length. In various embodiments, the neo-leaflet or part thereof is expandable.

20 In various embodiments, the coaptation structure or part thereof may be inserted via a commissure in between two heart valve leaflets to the ventricular side of the valve where once deployed, it prevents reflux of flow by acting as a one way valve together with the patient's heart valve leaflets.

25 In various embodiments, the coaptation structure may be inserted in the commissure in between two valve leaflets in order to act as a membrane wall structure on which the leaflets can coapt, thereby preventing their prolapse and flow regurgitation. In such embodiments, the coaptation structure is a membrane.

#### Connecting Means

30 In various embodiments, the deployable coaptation structure and the upstream anchoring means are a single unitary structure. In other various embodiments, the deployable coaptation structure and upstream anchoring means are separate structures, and the coaptation structure is attachable and securable to the upstream anchoring means by one or more connecting means. In various embodiments, the connecting means is adapted to arrange the coaptation  
35 structure at an intended location with respect to the valve/valve leaflets, e.g. centre of a heart valve.

40 The connecting means may be integral with the coaptation structure or the upstream anchoring means. The connecting means includes but is not limited to tethers, screws, mechanical locks, hooks, magnets, sutures (regardless of calibre or material), fabric, plication, crimps, staples, rivets, adhesives and any other device, component or method typically used to assemble various elements in an implantable device. The connecting means is preferably biocompatible and/or bio-inert.

It should be conceivable that there may be different sizes and shapes of the components of the cardiac valve repair device of the present invention, available to account for the distance between the tissue site at which the upstream anchoring means anchors and the heart valve being treated/repared, and the size of the heart valve being treated/repared. Therefore in various embodiments, the connecting means is capable of varying the distance between the upstream anchoring means and the coaptation structure, for example by varying its length. Therefore, the length of the connecting means will depend on the application of the present invention and requirements of the patient and/or the physician. Preferably, the connecting means is a tether (which includes rods and wires). A physician can measure the distance between the upstream anchoring means and the coaptation structure before determining the optimal length of the connecting means.

Tethers may be made from biocompatible and/or bio-inert materials which include but are not limited to polymers (such as PTFE and polypropylene), metals, metal alloys (such as nitinol-titanium) and tissue (natural or artificial/engineered). Tethers may be formed from a single wire or comprise more than one wire braided together. Tethers may be inelastic or elastic. Tethers may be flexible, which can contribute to the flexibility of the coaptation structure of the present invention.

#### Stabilizing Means

In various embodiments, the cardiac valve repair device comprises a stabilizing means that maintains an end of the coaptation structure at a downstream location with respect to a heart valve. The stabilizing means may be an extension of the coaptation structure, the upstream anchoring means or the connecting means. The stabilizing means extends substantially to a downstream location across the heart valve, e.g. into a heart ventricle and is connected via for example tethers, to an end of the coaptation structure to maintain its downstream location. Such tethers (stabilizing tethers) function in the similar manner like natural chordae tendinae which prevent the prolapse retraction of the coaptation structure, especially during systole, by becoming tense and pulling on the coaptation structure. In various embodiments where the coaptation structure is a neo-leaflet, such tethers prevent the eversion and prolapse of the neo-leaflet, especially during systole, by becoming tense and pulling on the neo-leaflet.

The stabilizing means may be made from metals, metal alloys, polymers, tissue (natural or artificial/engineered) or a combination thereof. The stabilizing means is preferably flexible and made from a shape memory material. Preferably, the stabilizing means is made from a material having a sufficiently high elasticity modulus that allows the stabilizing means to maintain its shape during operation. The stabilizing means may be made from metal, metal alloy, polymer or other man-made material, or a combination thereof. Preferably the stabilizing means comprises metals and/or metal alloys having shape memory, which includes but are not limited to nitinol titanium (nitinol), Cu-Zn-Al-Ni alloys and Cu-Al-Ni alloys. Preferably the stabilizing means is made from nitinol-titanium.

In various embodiments, the stabilizing means comprises a weighted end.

In various embodiments, the stabilizing means comprises one or more downstream anchoring means adapted to anchor the device to a tissue site, at a downstream location with respect to the heart valve, e.g. ventricular side of the valve. The stabilizing means stabilize the coaptation structure across the heart valve which may advantageously prevent the cardiac valve repair device from migrating over the cardiac cycle and over time.

The downstream anchoring means includes but is not limited to clamps, hooks, tines, barbs, screws and bio-adhesives. Where the downstream anchoring means is for example a clamp or hook, the downstream anchoring means is capable of piercing the intended tissue site for anchoring. Such tissue sites include but are not limited to endocardial and pericardial tissue sites.

The downstream anchoring means may be integral with the stabilizing means and can comprise tissue (natural or artificial/engineered), metals, metal alloys, polymers or other man-made materials, or a combination thereof. One or more downstream anchoring means may be used to anchor and secure the device of the present invention to one or more downstream tissue sites. Where more than one downstream anchoring means is used, the type of downstream anchoring means may be different from one another. The downstream anchoring means is preferably bio-inert and/or biocompatible.

#### Method of Delivery, Deployment and Implantation of the Cardiac Valve Repair Device

The present invention includes methods of delivery, deployment and implantation of the cardiac valve repair device of the present invention. The delivery of the cardiac valve repair device of the present invention may be a single or multi-step process. A method of delivering such device may comprise the use of a delivery catheter inserted through minimally invasive access and advanced by fluoroscopic and ultrasound (Echo) guidance. Echocardiographic and/or CT (computerized tomography) and/or MRI (magnetic resonance imaging) evaluation may be required pre-operatively to determine the 3D-relationship between the tissue site (e.g. coronary sinus) and the heart valve (e.g. tricuspid valve). It is expected that patients with a pacing lead in the coronary sinus or in the right ventricle may be unsuitable for this therapy. The methods of the present invention may also not be performed in patients with infective endocarditis.

In various particular embodiments, the method of delivery may include using access from the femoral vein, internal jugular or subclavian vein, to access the coronary sinus. A marker catheter may be used to size the coronary sinus. This can be performed by an imaging modality such as ultrasound echocardiography, Transesophageal echocardiography, intravascular ultrasound or by fluoroscopy with injection of contrast. The marker catheter is then exchanged for the delivery system, using a guidewire.

With the delivery system in place, the stent is deployed at the orifice of the coronary sinus and stability is verified. Stability testing may include tug testing. The deployable coaptation structure is then deployed, for example in the right atrium RA and guided into the right ventricle RV. This may be performed with a specialized catheter or part of the delivery catheter.

5

Alternatively, the coaptation structure is positioned directly in the right ventricle RV before full deployment, again by the delivery catheter. Once the coaptation structure is deployed, echocardiographic and fluoroscopic assessment can be performed to confirm device positioning and adequate reduction of tricuspid regurgitation. The upstream anchoring means (e.g. stent) of the device is then deployed to hold the coaptation structure in place as a secondary step.

10

Deployment of the coaptation structure may depend on its actual shape and size. It may be unfurled, untwisted, unsheathed, or unrolled. It may be deployed in a single or multi-step process.

15

In various embodiments, a delivery device, e.g. a delivery catheter carries the cardiac valve repair device of the present invention, where the device comprises the upstream anchoring means (e.g. a stent) and the coaptation structure (e.g. a neo-leaflet) as a single unitary structure. The coaptation structure may be deployed first followed by the upstream anchoring means or vice versa. For example where the cardiac valve repair device is adapted to treat/repair a tricuspid valve, the upstream anchoring means is a stent operable to anchor at the inferior vena cava and the coaptation structure comprises a neo-leaflet, the neo-leaflet can be deployed in the right ventricle and then withdrawn partially into the right atrium, and thereafter, the rest of the cardiac valve repair device is pulled back into the inferior vena cava where the stent is anchored to the inferior vena cava. Hence, the sequence of delivery of the cardiac valve repair device may be as follows:

20

25

- delivery system (delivery catheter comprising the cardiac valve repair device) is navigated from inferior vena cava to right atrium into right ventricle across tricuspid valve;
- the distal end of the neo-leaflet as the coaptation structure is released into the right ventricle and unfurled as the delivery catheter is pulled back into the right atrium where the proximal part of the neo-leaflet will sit/locate; and
- the catheter is pulled back further into the inferior vena cava where the stent as the upstream anchoring means is deployed with the neo-leaflet attached to the stent – the neo-leaflet may be integral with the stent, or be attached to the stent via a connecting means (e.g. bioadhesives, stitches, hooks and tethers).

30

35

In various embodiments, the delivery, deployment and implantation of the cardiac valve repair device comprises a multi-step process where for example, the upstream anchoring means, e.g. the stent is first delivered and anchored to the coronary sinus or inferior vena cava before

40

the coaptation structure, e.g. neo-leaflet is delivered and secured to the upstream anchoring means, and deployed across the tricuspid valve.

In one aspect, the present invention relates to a method of treating or repairing a heart valve by a minimally invasive approach, comprising the steps of advancing an upstream anchoring means to an anchoring location (preferably a vessel ostium) of a heart chamber, in the vicinity of the heart valve and deploying the upstream anchoring means at the location, and deploying the deployable coaptation structure (e.g. a neo-leaflet) and ensuring the function of the coaptation structure to restore valve function. The procedure may include advancing an additional catheter to pass the distal part of the coaptation structure across the valve. It is understood that these steps may be performed in a different reverse order.

In a particular embodiment of a tricuspid valve repair, the invention relates to a method of delivering and implanting a cardiac valve repair device of the present invention, the method comprising the steps of catheterizing the coronary sinus and delivering the upstream anchoring means, and deploying a coaptation structure (e.g. neo-leaflet) across the tricuspid valve to restore valve function. It is understood that each of the steps described above may occur in a different order.

In a particular embodiment of a mitral valve repair, the invention relates to a method of delivering and implanting a cardiac valve repair device of the present invention, the method comprising the steps of catheterizing one of the pulmonary veins and delivering the upstream anchoring means, and deploying a coaptation structure (e.g. a neo-leaflet) across the mitral valve to restore valve function. It is understood that each of the steps described above may occur in a different order.

In both tricuspid and mitral valve repairs, the delivery of the cardiac valve repair device can be advanced in the right or left atrium, via the femoral vein, internal jugular or subclavian vein and a transeptal puncture.

It is understood that while particular cases of tricuspid and mitral valve repair are described, a device according to the principles of the present invention may be used to correct valve regurgitation in the aortic valve or in the pulmonary valve as well.

In various embodiments, each component of the cardiac repair are retrievable and removable from a patient via the delivery catheter system.

#### Exemplary Embodiments of the Present Invention

##### ***Cardiac Valve Repair Device***

Figures 1 and 2 are schematic views of the heart 1 showing the anatomical relationship between the different valve positions in an axial view (Figures 1A and 1B) and a coronal view (Figure 2). The position of the ostia of coronary sinus 6 and pulmonary veins 7 can be

observed above the tricuspid valve 2 and the mitral valve 3 respectively. In Figure 2, a guidewire 50 is shown advanced into the coronary sinus 6 from the superior vena cava 8. During heart minimally invasive procedures, a guidewire 50 is often used during the heart catheterization to obtain a guide path from the access point to a desired location and to advance a guiding catheter sheath and other catheters to that particular desired location. Such a wire or guide catheter may be used here for advancing and delivering the cardiac valve repair device of the present invention into the coronary sinus 6.

Figures 3 to 5, 14 and 15 provide an embodiment of a cardiac valve repair device 10 of the present invention. Figure 3 shows a schematic magnified view of the anatomy shown in Figure 2, showing the right heart ventricle RV and tricuspid valve 2 with a cardiac valve repair device 10 according to an embodiment of the present invention. The cardiac valve repair device 10 comprises a stent 11 as an upstream anchoring means and a neo-leaflet 12 as a deployable coaptation structure. The neo-leaflet 12 extends from the stent 11 at a border 11a located at one end of the stent 11. Preferably, the neo-leaflet 12 extends from an inferior border 11a of the stent 11 such that when the device 10 is implanted in the correct orientation in the patient's heart, the neo-leaflet 12 is positioned close to the heart valve for said neo-leaflet 12 to function as described herein. The inferior border 11a will be understood to be a lower portion of an end of the stent 11 when the stent 11 is implanted in a correct orientation in for example the coronary sinus 6 (Figure 5C). In various embodiments, the inferior border 11a is the lowest tip of an end of the stent 11 when the stent 11 is implanted in a correct orientation. It will be appreciated that depending on the application and requirements, the neo-leaflet 12 (as the coaptation structure) is attachable to one or more portions of the stent 11 (as the upstream anchoring means) which includes but is not limited to an inner luminal surface, an outer luminal surface, and anywhere along the length of the stent 11, for example the end and medial portions of the stent 11. Preferably, the neo-leaflet 12 is attachable (e.g. via stitching, hooks and/or screws) to an inner border, surface, lumen and/or portion of the stent 11.

The stent 11 and neo-leaflet 12 form a unitary structure, where the material of the stent 11 is used to form a part of the neo-leaflet 12. With reference to Figure 14, the stent 11 is made from a metal alloy, preferably nitinol-titanium, comprising a portion which extends to form a structural support frame 12a that forms the leaflet/flap shape of the neo-leaflet 12. The structural support frame provides the neo-leaflet 12 with a curved side profile as shown in Figure 5A. Bioprosthetic material 12b is attached, e.g. via stitching, hooks and/or screws to the structural support frame 12a to complete the neo-leaflet 12. The structural support frame 12a holds the neo-leaflet 12 in position during operation of the device 10 and provides the required rigidity to the neo-leaflet 12 to prevent prolapse of the distal section of the neo-leaflet 12. The structural support frame 12a also provides the required flexibility for the neo-leaflet 12 to function in a substantially similar manner as a normal native valve leaflet for coaptation with the heart valve leaflets during operation. In various embodiments, the neo-leaflet 12 comprises a shape that substantially corresponds to the medial portion of the septal leaflet 2c.

In various embodiments, the stent 11 and neo-leaflet 12 are separate components, and the neo-leaflet 12 is attachable to the stent 11 at the border 11a via means and methods disclosed herein, for example via stitching, bioadhesives, hooks and/or screws.

5 The stent 11 is implantable in a coronary sinus 6, with the border 11a preferably located substantially at the ostium 6a of the coronary sinus 6. The stent 11 can be crimped/compressed and catheter delivered to the coronary sinus 6 before being expanded and implanted in the coronary sinus 6. The stability of the stent 11 in the coronary sinus 6 can be tested via tug testing. The neo-leaflet 12 is deployed and extends across the tricuspid valve  
10 2 and into the right ventricle RV, preferably via a location (first location) substantially at the centre of the tricuspid valve 2. In particular, the neo-leaflet 12 extends across the tricuspid valve 2 to locate a free end 12' of the neo-leaflet 12 downstream from the tricuspid valve 2, in the right ventricle RV. The free end 12' is preferably located downstream from the tricuspid valve 2 at all times when in operation, i.e. during both systolic and diastolic phases. The free  
15 end 12' is distal from the stent 11. The free end 12' is allowed to move substantially unrestricted during the cardiac cycle, but remains downstream from the heart valve. In various embodiments, the free end 12' is not anchored to a tissue site. When a heart valve is non-functional and regurgitation is present, the leaflets of the valve typically do not coapt together completely and instead of the valve closing, flow is regurgitating through an area of the valve  
20 into the atrium, affecting the heart pumping mechanism. The neo-leaflet 12 acts as a mechanism to restore the tricuspid valve 2 function, which is to close during the ventricular systolic phase in order for the blood in the right ventricle RV to be ejected through the pulmonary valve 5. As shown in Figures 3, 4 and 15, the neo-leaflet 12 extends onto at least one of the native valve leaflets, extending beyond it to increase the length available for  
25 coaptation. Therefore in operation, the neo-leaflet 12 is an extension of and functions like the septal leaflet 2c, which coapts against the anterior leaflet 2a and posterior leaflet 2b during ventricular systole, thereby preventing, reducing and/or minimizing backflow of blood (i.e. regurgitation). Preferably, the neo-leaflet 12 extends substantially onto the septal leaflet 2c. In various embodiments, portions of the neo-leaflet 12 extend into the right ventricle RV at other  
30 locations, for example via a commissure in between valve leaflets, for example commissure 2d, between posterior leaflet 2b and septal leaflet 2c.

The cardiac valve repair device 10 is advantageous because it can be implanted efficiently via minimally invasive means known in the art. The stent 11 can be easily anchored to the  
35 upstream tissue site which is a blood vessel, and the neo-leaflet 12 can be easily deployed to extend across the failing valve to expeditiously restore valve functions by coapting with the other valve leaflets.

Figure 6 provides another embodiment of a cardiac valve repair device 110 comprising a stent  
40 111 and a neo-leaflet 112 which is attached to the stent 111 via connecting tethers (connecting wires) 113. The neo-leaflet 112 is a petal/paddle-shaped flap. During operation of the device 110, the tethers 113 extend the deployed neo-leaflet 112 towards an intended location (e.g. the centre between valve leaflets) in the heart valve, arrange and substantially maintain the



orientation and position of the neo-leaflet 112 at the intended location(s). The positioning of the neo-leaflet 112 at the intended location(s) optimizes the efficiency of the device 110 in the repair/treatment of the heart valve by ensuring maximal coaptation between the valve leaflets and the neo-leaflet 112. The tethers 113 are therefore preferably made from a shape memory metal alloy, e.g. nitinol-titanium, such that they can effectively maintain the position of the neo-leaflet 112 at the intended location(s).

In Figure 6, the stent 111, neo-leaflet 112 and tethers 113 are a single unitary structure, where the tethers 113 extend from the stent 111 to the neo-leaflet 112 and forms the shape and structure of the neo-leaflet 112. It will however be appreciated that in other embodiments, the stent 111 and the neo-leaflet 112 are separate components, which are attachable to one another via the tethers 113. The attachment point may be at either or both ends of the tethers 113 (i.e. at the border 111a and/or the neo-leaflet 112), or at a medial portion of the tethers 113.

The tethers 113 are preferably flexible, thereby providing additional flexibility to the cardiac valve repair device 110 during operation. The length of the tethers 113 depends on the application of the present invention and the requirements of the patient and/or physician. For example, the tethers 113 can comprise a length that substantially corresponds to the distance of ostium 6a of the coronary sinus 6 to the tricuspid valve 2, of a patient. To avoid substantial variations in the length of the tethers 113 during operation, the tethers 113 are preferably non-elastic.

Figure 7 provides another embodiment of a cardiac valve repair device 210 comprising a stent 211 implanted into the coronary sinus 6, tether 213 and a coaptation structure 212 extending across the tricuspid valve 2 and into the right ventricle RV via a central location between tricuspid valve leaflets. During operation (i.e. during systolic and diastolic phase), the coaptation structure 212 extends across the tricuspid valve 2 to locate a free end 212' of the coaptation structure 212 downstream from the tricuspid valve 2, in the right ventricle RV. The coaptation structure 212 is a balloon 212 comprising a structure support frame 212a and an expandable portion 214 having a surface for coaptation with at least one valve leaflet so as to prevent, reduce and/or minimize a backflow of blood, when in operation.

The expandable portion 214 can be self-expandable or can be expanded via a balloon catheter. When in operation, the expandable portion 214 is positioned within the valve 2 via tethers 213 such that the expandable portion 214 or a portion thereof, provides a support for coaptation of valve leaflets. Therefore the expandable portion 214 comprises a length that sufficiently extends into the ventricle between valve leaflets, thereby providing a support for coaptation of the valve leaflets. Such length can depend on for example, the distance between the upstream tissue anchorage site and the valve, and/or the length of the heart valve leaflet. It will be appreciated that the length of heart valve leaflets are often mismatched, and therefore the different lengths of the heart valve leaflets have to be taken into consideration when determining the length of the expandable portion 214 (or a neo-leaflet). Accordingly, the

expandable portion 214 can extend the entire length (i.e. to the end) of the structural support frame 212a or a part thereof.

In other embodiments, the coaptation structure 212 is an expandable neo-leaflet 212, where  
5 a portion of the neo-leaflet 212, e.g. the portion comprising the bioprosthetic tissue, is expandable.

Figure 8 shows the cardiac valve repair device 10 of Figure 5 implanted above a mitral valve  
10 3 in the left atrium LA of a heart. The stent 11 of the device 10 is implanted into a pulmonary vein 7 and a neo-leaflet 12 extends from the stent 11 across the mitral valve and into the left ventricle LV. The neo-leaflet 12 preferably extends onto at least one mitral valve leaflet, and in between the mitral valve leaflets. In various embodiments, the device 10 comprises more than one upstream anchoring means, i.e. more than one stent 11, that may be implanted in more than one pulmonary vein 7 in the left atrium LA. The device 10 functions in the same  
15 manner as described above in relation to Figures 3 to 5, 14 and 15, for the tricuspid valve.

Figures 9A and 9B provides another embodiment of a cardiac valve repair device 310  
comprises a stent 311 implanted in a coronary sinus 6, and a coaptation structure 312. The coaptation structure 312 is a membrane 312 that is capable of extending between adjacent  
20 valve leaflets, e.g. posterior leaflet 2b and septal leaflet 2c, at the posteroseptal commissure 2d, into the right ventricle RV, where a free end 312' of the membrane 312 is positioned downstream from the tricuspid valve 2, in the right ventricle RV. The membrane 312 functions as a septum which enhances coaptation of the valve leaflets 2b, 2c. The membrane 312 preferably extends across the tricuspid valve 2 via commissure 2d to act as a membrane wall  
25 structure on which the leaflets can coapt, thereby preventing their prolapse and flow regurgitation.

Figures 10A and 10B provides another embodiment of a cardiac valve repair device 410  
comprising a stent 411 implanted into a coronary sinus 6, tethers 413, a backflow barrier 412,  
30 and legs 415 (second upstream anchoring means). The legs 415 extend to the opposite side of the right atrium RA, i.e. opposite from the coronary sinus 6. The backflow barrier 412 is positioned by the tethers 413 and the legs 415 centrally above and close to the area of regurgitation (e.g. in between and superior to the valve leaflets) to prevent regurgitation of the blood flow in the defective valve during the cardiac cycle. The legs 415 maintain stability of  
35 the backflow barrier 412, which acts as a repair structure by preventing prolapse of defective valve leaflets.

In various embodiments, the backflow barrier 412 has substantially the same structure as a  
neo-leaflet (e.g. neo-leaflet 12) of the present invention, although the backflow barrier 412  
40 does not coapt with the valve leaflets when in operation. In such embodiments, the backflow barrier 412 comprises a flexible structural support frame that is shaped like a leaflet or a flap, and a bioprosthetic tissue that is attached to the frame. The backflow barrier 412 is preferably flexible. Preferably, the backflow barrier 412 is substantially planar.

The legs 415 can extend from the tethers 413 or from the end (distal from the stent 411) of the backflow barrier 412 depending on the application and requirements. The legs 415 may be part of a unitary structure of the device 410 or a separate component attachable to the device 410. The ends of the legs 415 are shaped to engage/abut a wall of the atrium, which provides a resistive force to maintain the position of the device 410 and the backflow barrier 412 with respect to the tricuspid valve 2. In various embodiments, the ends of the legs 415 are configured to anchor to the wall of the atrium, for example the ends of the legs 415 comprise clamps that are adapted to pierce the atrial wall to anchor the device 410 in the atrium. The legs 415 may be made of the same material as the stent 411, tether 413 and/or the structural support frame of the backflow barrier 412. In various embodiments, the device 410 may comprise a single leg 415 or more than two legs 415. Preferably, the device 410 comprises at least one leg 415 as a second upstream anchoring means.

Figure 11 provides another embodiment of a cardiac valve repair device 510 comprising a stent 511 implanted into a coronary sinus, tethers 513, a neo-leaflet 512 that extends from the stent 511 via tethers 513 and a downstream anchoring means 516 distal from the stent 511. The downstream anchoring means 516 is connected to an end of the neo-leaflet 512 distal from the stent 511, and may be unitary with the neo-leaflet 512. In other embodiments where the downstream anchoring means 516 is a separate component from the neo-leaflet 512, the downstream anchoring means 516 is attachable to an end of the neo-leaflet 512 via means as described in the specification herein. A downstream connecting means may be used to connect the end of the neo-leaflet 512 and the downstream anchoring means 516.

The neo-leaflet 512 extends across the tricuspid valve 2 into the right ventricle RV, in between the tricuspid valve leaflets, where the downstream anchoring means 516 is configured to anchor to a tissue site in the right ventricle RV, downstream from the tricuspid valve 2. The downstream anchoring means 516 cooperates with the stent 511 and tethers 513 to maintain the neo-leaflet 512 at the intended location between the valve leaflets. Maintenance of the coaptation structure at the intended location between the valve leaflets preferably avoids the coaptation structure (for example where the coaptation structure is a balloon) from getting struck in an offset position in the commissures between the valve leaflets, which can result in leakage of the valve.

Additionally, the downstream anchoring means 516 functions as a restraint in the prevention of prolapse of the neo-leaflet 512 into the right atrium RA, during right ventricular systole. The downstream anchoring means 516 may be anchored at an endocardial or pericardial tissue site. The downstream anchoring means 516 can comprise tines, barbs, screws and/or clamps that are capable of piercing the cardiac wall for anchorage.

Figures 12A and 12B provides another embodiment of a cardiac valve repair device 610 comprising a stent 611 implanted in the inferior vena cava 9, and a neo-leaflet 612 that extends from the stent 611 into the right ventricle RV across the tricuspid valve 2, such that a free end

612' of the neo-leaflet 612 locates in the right ventricle RV, downstream of the tricuspid valve 2. The device 610 can comprise tethers that lengthens the device 610 to extend the neo-leaflet 612 into the right ventricle RV. In the present embodiment, the neo-leaflet 612 extends onto the anterior leaflet 2a of the tricuspid valve 2.

5

In various embodiments, the device can comprise an additional upstream anchoring means that anchors to a tissue site upstream from the heart valve, for example, the device 610 can comprise a second stent that is implantable into the superior vena cava, and cooperates with the stent 611 in the inferior vena cava to secure and position the neo-leaflet 612 at an intended location with respect to the tricuspid valve. In other various embodiments, the stent 611 may be implanted in the superior vena cava instead of the inferior vena cava.

10

Figure 13 provides another embodiment of a cardiac valve repair device 710 comprising a stent 711 implanted in the inferior vena cava 9, a neo-leaflet 712 that extends from the stent 711 into the right ventricle RV across the tricuspid valve 2, and a downstream anchoring means 716 distal from the stent 711 and extending from an end of the neo-leaflet 712.

15

The neo-leaflet 712 extends into the right ventricle RV in between the tricuspid valve leaflets, where the downstream anchoring means 716 is configured to anchor to a tissue site in the right ventricle RV, downstream from the tricuspid valve 2. The downstream anchoring means 716 cooperates with the stent 711 to maintain the neo-leaflet 712 at the intended location between the valve leaflets. Maintenance of the coaptation structure at the intended location between the valve leaflets preferably avoids the coaptation structure (for example where the coaptation structure is a balloon) from getting struck in an offset position in the commissures between the valve leaflets, which can result in leakage of the valve.

20

25

Additionally, the downstream anchoring means 716 functions as a restraining means in the prevention of prolapse of the neo-leaflet 712 into the right atrium RA, during right ventricular systole. The downstream anchoring means 716 may be anchored at an endocardial or pericardial tissue site. The downstream anchoring means 716 can comprise tines, barbs and/or clamps that are capable of piercing the cardiac wall for anchorage.

30

Figures 16A and 16B provide another embodiment of a cardiac valve repair device 810 comprising a stent 811 implanted into a coronary sinus 6, a neo-leaflet 812 having a distal free end 812' extending into the right ventricle across the tricuspid valve 2, a tether 813 connecting an end border of the stent 811 to a proximal end of the neo-leaflet 812, and a stabilizing means 817 that extends further into the right ventricle with respect to the free end 812'. The neo-leaflet 812 preferably extends onto at least one tricuspid valve leaflet. The stabilizing means 817 extends from the tether 813 and/or the stent 811, below an inferior surface of the neo-leaflet 812 and into the right ventricle, across the tricuspid valve 2. In various embodiments, the inferior surface of the neo-leaflet 812 or a part thereof is connected to the stabilizing means 817.

35

40

The stabilizing means 817 comprises a wire or a plurality of wires formed from a shape memory metal alloy that is flexible, e.g. nitinol-titanium. The stabilizing means 817 is attached via one or more stabilizing tethers 818 to the neo-leaflet 812 at a portion substantially close to or at the free end 812', such that the stabilizing means 817 forms an extension of the free end 812'. The stabilizing means 817 is shaped (e.g. curved downwards towards a ventricular apex) to maintain the free end 812' of the neo-leaflet 812 in the right ventricle during the cardiac cycle, by maintaining a restraining force in the direction downstream from the valve. Therefore, during a ventricular systole, the stabilizing means 817 exerts a counter force in an opposite direction of the blood flow against the valve so as to prevent prolapse of the neo-leaflet 812. The stabilizing means 817 exerts this tensional/restraining force via stabilizing tethers 818. The stabilizing tethers 818 function like chordae tendineae which prevent the eversion and prolapse of the neo-leaflet 812, especially during systole, by becoming tense and pulling the neo-leaflet 812, holding it in a closed coaptation position with the other valve leaflets.

The stabilizing means 817 comprises a weighted end 816a distal from the neo-leaflet 812 that preferably assists via gravity, in the extension of the stabilizing means 817 in the ventricle. The weighted end 816a may be a free end which moves freely within the ventricle, or an end that abuts against a ventricular wall to aid in the positioning of the neo-leaflet 812 at an intended location with respect to the heart valve. The stabilizing tethers 818 are attached to the weighted end 816a. In other embodiments, the stabilizing tethers 818 are attached to other portions of the stabilizing means 817. In other various embodiments, the weighted end 816a is a downstream anchoring means operable to anchor to a tissue site downstream with respect to the valve.

In other various embodiments, the stabilizing means 817 is attached to the free end 812' of the neo-leaflet 812, such that the stabilizing means 817 can be considered an extension of the neo-leaflet 812 and the weighted end 816a can be considered an extension of the free end 812'. In such embodiments, the stabilizing means 817 may not comprise stabilizing tethers 818 since the weighted end 816a would be sufficient to maintain the free end 812' of the neo-leaflet 812 in the ventricle.

#### ***Methods of Delivery, Deployment and Implantation of the Cardiac Valve Repair Device***

Figures 17A to 17F illustrate steps of a method for delivering, deploying and implanting a cardiac valve repair device 10 according to the embodiment shown in Figures 3 to 5, 14 and 15. The cardiac valve repair device 10 comprises an anchoring device, a stent 11, and a neo-leaflet 12 which are separate components that are adapted to be connected together *in vivo*.

Referring to Figure 17A, the stent 11 is delivered via the inferior vena cava 9 in a direction B to the coronary sinus 6 of a right heart atrium RA by a first delivery catheter 51. Access to the right heart atrium RA may be from the femoral vein, internal jugular or subclavian vein. A guide wire (not shown) may be used to guide the first delivery catheter 51 to the intended location in the patient's heart. The stent 11 is preferably crimped/compressed and may be enveloped (wholly or in part) by the delivery catheter, such that upon reaching the intended location, the

stent 11 is unsheathed for the purposes of anchoring to an upstream tissue site. The stent 11 is preferably crimped/compressed during transcatheter delivery to allow for relatively smooth tracking of the system through the blood vessels to an intended tissue site. Further, it allows the stent 11 to fit within a lumen of a blood vessel (e.g. coronary sinus) that is intended to be the upstream tissue site for anchorage. The stent 11 is positioned by the first delivery catheter 51 within the coronary sinus 6 such that upon anchorage, one end of the stent 11 is contiguous with the ostium 6a of the coronary sinus 6, as shown in Figure 17B.

Upon reaching the coronary sinus 6, the stent 11 is radially expanded by for example a balloon catheter, to urge and secure the stent 11 against and engage the luminal wall of the coronary sinus 6. The engagement of the stent 11 against the luminal wall of the coronary sinus 6 provides a resistive force that anchors the stent 11 within the coronary sinus 6. When expanded, the stent 11 is substantially rigid to prevent collapse of the stent 11 during operation of the cardiac valve repair device 10. After the stent 11 is anchored to the coronary sinus 6, the stability of the stent 11 may be tested by tug testing which includes tugging on the stent 11 to check if the stent 11 will dislodge from the coronary sinus 6. The first delivery catheter 51 may be fully retracted for subsequent steps of the method to take place.

A second delivery catheter 51' delivers the neo-leaflet 12 in a direction B via the inferior vena cava 9 to the coronary sinus 6 where the stent 11 is anchored (Figure 17C). A guide wire (not shown) may be used to guide the second delivery catheter 51' to the coronary sinus 6. The neo-leaflet 12 is preferably compressible/crimpable and may be enveloped (wholly or in part) by the delivery catheter, such that upon reaching the intended location, the neo-leaflet 12 is unsheathed and unfurled for deployment. The neo-leaflet 12 is preferably crimped/compressed during transcatheter delivery to allow for relatively smooth tracking of the system through the blood vessels to the intended location. In various embodiments, the neo-leaflet 12 is releasably attached to an end of the second delivery catheter 51'. The second delivery catheter 51' extends substantially within the coronary sinus 6 in the direction B to contact the neo-leaflet 12 with the interior surface of the stent 11, which can assist in the positioning of the neo-leaflet 12 for attachment with the stent 11.

The second delivery catheter 51' is thereafter moved in a direction B' (Figure 17D) to position one end of the neo-leaflet 12 with an inferior border of the stent 11, where the neo-leaflet 12 is attached to the inferior border of the stent 11 via a connecting means (e.g. bioadhesives, stitchings, hooks and screws) as described herein. As shown in Figure 17E, the second delivery catheter 51' is fully retracted and neo-leaflet 12 extends from the stent 11. In various embodiments, the neo-leaflet 12 naturally extends across the tricuspid valve 2 for coaptation with at least one valve leaflet to prevent, reduce and/or minimize a backflow of blood. In other various embodiments and as shown in Figure 17F, a guide wire 50 is advanced in a downstream direction C to urge the neo-leaflet 12 to position across the tricuspid valve 2.

Figures 18A to 18D illustrate steps of a method for delivering, deploying and implanting a cardiac valve repair device 610 according to the embodiment shown in Figures 12A and 12B.

The cardiac valve repair device 610 comprises a stent 611 and a neo-leaflet 612 which are unitary, or separate components that are adapted to be connected together *ex vivo*.

Referring to Figure 18A, the cardiac valve repair device 610 is delivered via the inferior vena cava 9 the right side of a heart by a delivery catheter 651. The device 610 is preferably compressible/crimpable and may be enveloped (wholly or in part) by the delivery catheter, such that upon reaching the intended location, the device 610 is unsheathed. The delivery catheter 651 is advanced to the right ventricle RV such that an end of the delivery catheter 651 is positioned within the right ventricle RV, so that upon unsheathing the device 610 (e.g. via an obturator), a free end of the neo-leaflet 612 may be positioned within the right ventricle RV and the neo-leaflet 612 extends across the tricuspid valve 2. The delivery catheter 651 is retracted in the direction D to first expose and unsheathe the neo-leaflet 612 and thereafter the stent 611 (Figure 18B).

The delivery catheter 651 continues moving in the direction D to locate the stent 611 substantially within the inferior vena cava 9. The stent 611 is connected/attached to the neo-leaflet 612 via tethers 613 to provide sufficient length between the stent 611 and the neo-leaflet 612 for the neo-leaflet 612 to extend across the tricuspid valve 2 during operation of the device 610. In various embodiments where the neo-leaflet 612 is sufficiently long, one end of the neo-leaflet 612 is connected/attached to one end of the stent 611 (e.g. with bioadhesives), without the use of tethers. When the stent 611 is located substantially within the inferior vena cava 9, the stent 611 is radially expanded by for example a balloon catheter, to urge and secure the stent 611 against and engage the luminal wall of the inferior vena cava 9. The engagement of the stent 611 against the luminal wall of the inferior vena cava 9 provides a resistive force that anchors the stent 611 within the inferior vena cava 9. When expanded, the stent 611 is substantially rigid to prevent collapse of the stent 611 during operation of the cardiac valve repair device 610. After the stent 611 is anchored to the inferior vena cava 9, the stability of the stent 611 may be tested by tug testing which includes tugging on the stent 611 to check if the stent 611 will dislodge from the inferior vena cava 9. The delivery catheter 651 is then fully retracted to complete the implantation of the device 610 (Figure 18D), where the neo-leaflet 612 extends across the tricuspid valve 2.

Figures 19A to 19D illustrate steps of another method for delivering, deploying and implanting a cardiac valve repair device 610 according to the embodiment shown in Figures 12A and 12B. The cardiac valve repair device 610 comprises a stent 611 and a neo-leaflet 612 which are separate components that are adapted to be connected together *in vivo*.

Referring to Figure 19A, the stent 611 is delivered to the inferior vena cava 9 by a first delivery catheter (not shown). Upon reaching the inferior vena cava 9, the crimped/compressed stent 611 is radially expanded by for example a balloon catheter, to urge the stent 611 against and engage the luminal wall of the inferior vena cava 9. The engagement of the stent 611 against the luminal wall of the inferior vena cava 9 provides a resistive force that anchors the stent 611 within the inferior vena cava 9. When expanded, the stent 611 is substantially rigid to

prevent collapse of the stent 611 during operation of the cardiac valve repair device 610. After the stent 611 is anchored to the inferior vena cava 9, the stability of the stent 611 may be tested by tug testing which includes tugging on the stent 611 to check if the stent 611 will dislodge from the inferior vena cava 9.

5

A second delivery catheter 651' delivers in a direction E, the neo-leaflet 612 via the inferior vena cava 9 and through the stent 611, to the right heart atrium RA and the right heart ventricle RV (Figures 19B and 19C). The delivery catheter 651' is advanced to the right ventricle RV such that an end of the delivery catheter 651' is positioned within the right ventricle RV, so that upon unsheathing the neo-leaflet 612 (e.g. by an obturator), a free end of the neo-leaflet 612 may be positioned within the right ventricle RV and the neo-leaflet 612 may extend across the tricuspid valve 2. The delivery catheter 651 is retracted in the direction E' to expose and unsheathe the neo-leaflet 612 (Figure 19C), and to bring one end of the neo-leaflet 612 close to the stent 611.

10

15

After the neo-leaflet 612 has been positioned to extend across the tricuspid valve 2, the neo-leaflet 612 is connected to the stent 611 via tethers 613. The tethers 613 provide sufficient length between the stent 611 and the neo-leaflet 612 for the neo-leaflet 612 to extend across the tricuspid valve 2 during operation of the device 610. In various embodiments where the neo-leaflet 612 is sufficiently long, one end of the neo-leaflet 612 is connected/attached to one end of the stent 611 (e.g. with bioadhesives), without the use of tethers.

20

It should be understood that while certain variants of the present invention are illustrated and described herein, the invention is defined by the description and is not to be limited to the specific embodiments described and shown in the figures. For example, according to the invention is also conceivable that:

25

- the upstream anchoring means described herein as a stent can be made of another anchoring expandable structure or a screw;
- the coaptation structure deployed inside a patient's heart valve to restore valve function can be a spherical or tubular member or a prosthetic replacement valve;
- the device of the present invention can be applied to valve anatomies other than the tricuspid valve, for example the mitral valve;
- the device of the present invention can comprise methods of delivering, deploying and anchoring/implanting the neo-leaflet/flap to restore valve function and coaptation of the valve leaflets, other than the methods described herein; and
- various components of the cardiac valve repair device can be combined with one another even if not explicitly disclosed, for example, the device can comprise a superior vena cava anchoring stent, a neo-leaflet that extends onto the anterior leaflet of a

30

35

40



tricuspid valve and into the right ventricle, and a stabilizing means that extends further into the right ventricle with respect to the neo-leaflet, where the stabilizing means maintains a free end of the neo-leaflet in the ventricle.

## 5 REFERENCES

1. Tang GH, David TE, Singh SK, Maganti MD, Armstrong S, Borger MA. Tricuspid valve repair with an annuloplasty ring results in improved long-term outcomes. *Circulation* 2006;114:1577-81.
2. McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve repair: durability and risk factors for failure. *The Journal of thoracic and cardiovascular surgery* 2004;127:674-85.
3. Ghanta RK, Chen R, Narayanasamy N, et al. Suture bicuspidization of the tricuspid valve versus ring annuloplasty for repair of functional tricuspid regurgitation: midterm results of 237 consecutive patients. *The Journal of thoracic and cardiovascular surgery* 2007;133:117-26.
4. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). *The American journal of cardiology* 1999;83:897-902.
5. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. *Journal of the American College of Cardiology* 2004;43:405-9.
6. Izumi C, Iga K, Konishi T. Progression of isolated tricuspid regurgitation late after mitral valve surgery for rheumatic mitral valve disease. *The Journal of heart valve disease* 2002;11:353-6.
7. Porter A, Shapira Y, Wurzel M, et al. Tricuspid regurgitation late after mitral valve replacement: clinical and echocardiographic evaluation. *The Journal of heart valve disease* 1999;8:57-62.
8. Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. *Circulation* 2005;112:1453-7.

**Claims**

1. A device for cardiac valve repair, the device comprising:
  - at least one upstream anchoring means adapted to anchor to at least one tissue site, the tissue site located upstream with respect to a heart valve of a patient;
  - and
  - a coaptation structure arranged to extend from the upstream anchoring means, the coaptation structure comprising a free end,wherein the coaptation structure is operable to extend across the heart valve and locate the free end downstream from the heart valve and the coaptation structure operable to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood.
2. The device according to claim 1, wherein coaptation structure is flexible.
3. The device according to claim 1 or 2, wherein the coaptation structure comprises a balloon having a surface for coaptation of at least one heart valve leaflet of the patient's heart.
4. The device according to claim 3, wherein the balloon is expandable.
5. The device according to claim 3 or 4, the device further comprising a connecting means adapted to connect the upstream anchoring means and the balloon, wherein the connecting means is adapted to arrange the balloon at a first location between two or more heart valve leaflets of the patient's heart.
6. The device according to claim 2, wherein the coaptation structure comprises a neo-leaflet.
7. The device according to claim 6, wherein the neo-leaflet comprises a means for providing structure to the neo-leaflet and wherein said means is flexible.
8. The device according to claim 6 or 7, wherein the neo-leaflet comprises a polymer, fabric, tissue or combination thereof.
9. The device according to any one of claims 6 to 8, wherein the neo-leaflet is expandable.
10. The device according to any one of claims 6 to 9, the device further comprising a connecting means adapted to connect the upstream anchoring means and the neo-leaflet, wherein the connecting means is adapted to arrange a portion of the neo-leaflet at a first location between two or more heart valve leaflets of the patient's heart.

11. The device according to any one of claims 6 to 10, wherein the neo-leaflet is extendable onto a surface of at least one heart valve leaflet of the patient's heart.
12. The device according to any one of claims 6 to 11, wherein at least a portion of the neo-leaflet is extendable into a commissure between two adjacent heart valve leaflets of the patient's heart.
13. The device according to any one of claims 6 to 12, wherein the device comprises a stabilizing structure adapted to extend across the heart valve of the patient, and wherein the stabilizing structure is configured to maintain the downstream location of the free end of neo-leaflet.
14. The device according to claim 13, wherein the stabilizing structure comprises a weighted free end.
15. The device according to claim 13 or 14, wherein the stabilizing structure comprises one or more stabilizing tether adapted to connect the stabilizing structure to the neo-leaflet.
16. The device according to claim 15, wherein the stabilizing tether is adapted to connect to the free end of the neo-leaflet.
17. The device according to claim 2, wherein the coaptation structure comprises a membrane, wherein a portion of the membrane is extendable into a commissure between two adjacent heart valve leaflets of the patient's heart.
18. The device according to any one of the preceding claims, wherein the upstream tissue site is a blood vessel and the upstream anchoring means is a stent.
19. The device according to claim 18, wherein the heart valve is a tricuspid valve.
20. The device according to claim 19, wherein the stent is adapted to anchor at the coronary sinus of the patient's heart.
21. The device according to claim 19 or 20, wherein the stent is adapted to anchor at the inferior vena cava of the patient.
22. The device according to claim 21, the device comprising a second upstream anchoring means, wherein the second upstream anchoring means is a stent adapted to anchor at the superior vena cava of the patient.
23. The device according to claim 18, wherein the heart valve is a mitral valve and the stent is adapted to anchor at a pulmonary vein of the patient's heart.

24. The device according to any one of the preceding claims, wherein the upstream anchoring means and the coaptation structure are separate components of the cardiac valve repair device and wherein the upstream anchoring means and the coaptation structure are configured to connect with one another.
25. The device according to any one of claims 1 to 23, wherein the upstream anchoring means and the coaptation structure are a unitary structure.
26. The device according to any one of the preceding claims, wherein the device is crimpable or compressible for transcatheter delivery.
27. A method of implanting a device for cardiac valve repair in a patient's heart, the method comprising the steps of:
  - a) delivering a device for cardiac valve repair to the patient's heart, the device comprising at least one upstream anchoring means and a coaptation structure arranged to extend from the upstream anchoring means;
  - b) anchoring the upstream anchoring means to at least one tissue site in the patient's heart, the tissue site located upstream with respect to a heart valve of the patient's heart;
  - c) deploying the coaptation structure to extend across the heart valve to locate a free end of the coaptation structure downstream from the heart valve, and for the coaptation structure to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood.
28. The method according to claim 27, wherein the upstream anchoring means and the coaptation structure are separate components and the method comprises delivering the upstream anchoring means and the coaptation structure separately to the patient's heart.
29. The method according to claim 28, wherein the method further comprises the step of connecting the upstream anchoring means with the coaptation structure.
30. The method according to claim 29, wherein the upstream anchoring means and the coaptation structure are connected via a connecting means.
31. The method according to any one of claims 27 to 30, wherein the method further comprises the step of testing and verifying the stability of the upstream anchoring means.
32. The method according to any one of claims 27 to 30, wherein the method comprises deploying the coaptation structure before anchoring the upstream anchoring means.

33. The method according to any one of claims 27 to 32, wherein the coaptation structure is expandable and the method further comprises the step of expanding the coaptation structure.
34. The method according to any one of claims 27 to 33, wherein the upstream anchoring means is a stent and the method comprises anchoring the stent at the coronary sinus of the right atrium of the patient's heart, and deploying the coaptation structure such that the free end of the coaptation structure extends into the right heart ventricle of the patient and the coaptation structure coapts with at least one tricuspid valve leaflet of the patient's heart.
35. The method according to any one of claims 27 to 33, wherein the upstream anchoring means is a stent and the method comprises anchoring the stent at the inferior vena cava of the patient, and deploying the coaptation structure such that the free end of the coaptation structure extends into the right heart ventricle of the patient and the coaptation structure coapts with at least one tricuspid valve leaflet of the patient's heart.
36. The method according to claim 35, wherein the cardiac valve repair device comprises a second upstream anchoring means, wherein the second upstream anchoring means is a second stent and the method comprises anchoring the second stent at the superior vena cava of the patient.
37. The method according to any one of claims 27 to 33, wherein the upstream anchoring means is a stent and the method comprises anchoring the stent at a pulmonary vein of the left atrium of the patient's heart, and deploying the coaptation structure such that the free end of the coaptation structure extends into the left heart ventricle of the patient and the coaptation structure coapts with at least one mitral valve leaflet of the patient's heart.
38. The method according to any one of claims 27 to 37, wherein the delivery of the cardiac valve repair device is via transcatheter delivery.
39. The method according to any one of claims 27 to 38, wherein the delivery of the cardiac valve repair device is under fluoroscopic or ultrasound imaging guidance.
40. The method according to any one of claim 27 to 39, wherein the coaptation structure comprises a neo-leaflet.
41. A device for cardiac valve repair, the device comprising:
  - a first upstream anchoring means adapted to anchor to a first tissue site in a patient's heart;

- a second upstream anchoring means adapted to engage a second tissue site in the patient's heart; and  
a flexible backflow barrier arranged between, and extending from the first and second upstream anchoring means,  
wherein the first and second tissues site are located upstream with respect to a heart valve of the patient and the backflow barrier is arranged close to the heart valve of the patient to prevent and/or minimize backflow of blood.
42. The device according to claim 41, wherein the backflow barrier is substantially planar.
43. The device according to claim 41 or 42, wherein the backflow barrier comprises a neo-leaflet having a flexible frame.
44. The device according to claim 43, wherein the neo-leaflet comprises a polymer, fabric, tissue or combination thereof.
45. The device according to any one of claims 41 to 44, wherein the first upstream anchoring means is adapted to anchor at the coronary sinus of the patient's heart and the second upstream anchoring means is adapted to abut against a portion of the right arterial wall of the patient's heart.
46. The device according to any one of claims 41 to 44, wherein the first upstream anchoring means is adapted to anchor at the pulmonary vein of the patient's heart and the second upstream anchoring means is adapted to abut against a portion of the left arterial wall of the patient's heart.
47. A device for cardiac valve repair, the device comprising:  
an upstream anchoring means adapted to anchor to an upstream tissue site, the upstream tissue site located upstream with respect to a heart valve of a patient; and  
a neo-leaflet arranged to extend from the upstream anchoring means,  
wherein the neo-leaflet is operable to extend across the heart valve and the coaptation structure is operable to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood.
48. The device according to claim 47, wherein the device comprises a downstream anchoring means configured to extend from an end of the neo-leaflet, and wherein the downstream anchoring means is adapted to anchor at a downstream tissue site with respect to the heart valve of the patient.
49. The device according to claim 48, wherein the downstream tissue site is an endocardial or pericardial tissue site of a heart ventricle of the patient.

50. The device according to any one of claims 47 to 49, wherein the upstream anchoring means is adapted to anchor at the coronary sinus of the patient's heart.
51. The device according to any one of claims 47 to 49, wherein the upstream anchoring means is adapted to anchor to a pulmonary vein of the patient's heart.

1/12




Figure 1A




Figure 1B




Figure 2




Figure 3



2/12




Figure 4




Figure 5A




Figure 5B




Figure 5C

3/12




Figure 6




Figure 7








Figure 8

4/12






Figure 11




Figure 12A




Figure 12B




Figure 13




Figure 14




Figure 15

7/12




Figure 16A




Figure 16B

8/12




Figure 17A




Figure 17B

9/12




Figure 17C




Figure 17D



10/12




Figure 17E




Figure 17F

11/12




Figure 18A




Figure 18B




Figure 18C




Figure 18D

12/12




Figure 19A




Figure 19B




Figure 19C




Figure 19D

## INTERNATIONAL SEARCH REPORT

 International application No.  
**PCT/SG2017/050296**

## A. CLASSIFICATION OF SUBJECT MATTER

**A61F 2/24 (2006.01)**

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases: EPODOC, Espacenet, Auspat and Google Patents.

CPC/IPC Marks: A61F2/24

Espacenet and Google Patents were viewed according to keywords, the keywords used were as follows: coaptation, regulate, adjust, stop, heart, valve, leaflet, backflow, blood, anchor, secure, hook and like terms.

Applicant/Inventor Name Search: Espacenet, Auspat and Google Patents, Applicant (Singapore Health Services Pte. Ltd.) and Inventor (Yeo, Foin). Applicant (Singapore Health Services Pte. Ltd.) and Inventor (Yeo, Foin) names searched in internal databases provided by IP Australia.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	



Further documents are listed in the continuation of Box C



See patent family annex

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 4 September 2017	Date of mailing of the international search report 04 September 2017
<b>Name and mailing address of the ISA/AU</b>  AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au	<b>Authorised officer</b>  Ian Carroll AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. +61262832277

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/SG2017/050296
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2015/0112429 A1 (MIDDLE PEAK MEDICAL, INC.) 23 April 2015 Abstract; Claims 1, 6, 14, 16, 19; paragraphs [0008, 0026, 0031, 0071, 0074]; Figures 3H, 4D-4E, 9	1-2, 17, 24-30, 32-33, 39
Y	Abstract; Claims 1, 6, 14, 16, 19; paragraphs [0008, 0026, 0031, 0071, 0074]; Figures 3H, 4D-4E, 9	3-16, 18-23, 31, 34-38, 40, 47-51
Y	US 2014/0172070 A1 (SEGUIN) 19 June 2014 Abstract; Claim 21; paragraph [0001]	3-5, 38
Y	US 2008/0140190 A1 (MACOVIK et al.) 12 June 2008 Abstract; Figures 4, 8	6-16, 40, 47-51
Y	US 8016882 B2 (MACOVIK et al.) 13 September 2011 Figures 9-12; Claim 1	10-16
Y	US 4994077 A (DOBBEN) 19 February 1991 Abstract; paragraph [0035]	18-23, 37
Y	US 7972378 B2 (TABOR et al.) 05 July 2011 Figures 36-39	50
Y	US 2009/0043381 A1 (MACOVIK et al.) 12 February 2009 Claim 4; paragraph [0094]	18-23, 34-36, 51
Y	US 2005/0038470 A1 (VAN DER BURG et al.) 17 February 2005 paragraphs [0028,0029]	31

**Supplemental Box****Continuation of: Box III**

This International Application does not comply with the requirements of unity of invention because it does not relate to one invention or to a group of inventions so linked as to form a single general inventive concept.

This Authority has found that there are different inventions based on the following features that separate the claims into distinct groups:

- (1) Claims 1-40, 47-51 are directed to a device/method for cardiac valve repair. The feature of a coaptation structure extending from upstream anchoring means and having with a free end, the coaptation structure is operable to extend across the heart valve and locate the free end downstream from the heart valve to coapt with at least one heart valve leaflet of the patient's heart is specific to this group of claims.
- (2) Claims 41-46 are directed to a device for cardiac valve repair. The feature of two upstream anchoring means and a flexible backflow barrier arranged between them and located upstream with respect to the heart valve is specific to this group of claims.

PCT Rule 13.2, first sentence, states that unity of invention is only fulfilled when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features. PCT Rule 13.2, second sentence, defines a special technical feature as a feature which makes a contribution over the prior art.

When there is no special technical feature common to all the claimed inventions there is no unity of invention.

In the above groups of claims, the identified features may have the potential to make a contribution over the prior art but are not common to all the claimed inventions and therefore cannot provide the required technical relationship. The only feature common to all of the claimed inventions and which provides a technical relationship among them is

an upstream anchoring means adapted to anchor to a tissue site in a patient's heart and a structure extending from the upstream anchoring means and operable to prevent and/or minimize backflow of blood.

However this feature does not make a contribution over the prior art because it is disclosed in:

D1

Therefore in the light of this document this common feature cannot be a special technical feature. Therefore there is no special technical feature common to all the claimed inventions and the requirements for unity of invention are consequently not satisfied *a posteriori*.

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
the subject matter listed in Rule 39 on which, under Article 17(2)(a)(i), an international search is not required to be carried out, including
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

**See Supplemental Box for Details**

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
**1-40, 47-51**

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 2015/0112429 A1	23 April 2015	US 2015112429 A1	23 Apr 2015
		US 9610163 B2	04 Apr 2017
		CA 2825520 A1	02 Aug 2012
		CA 2877344 A1	27 Dec 2013
		CN 103338726 A	02 Oct 2013
		CN 103338726 B	11 May 2016
		CN 104582637 A	29 Apr 2015
		EP 2667823 A1	04 Dec 2013
		EP 2863844 A1	29 Apr 2015
		HK 1189792 A1	04 Aug 2017
		HK 1209616 A1	08 Apr 2016
		JP 2014510563 A	01 May 2014
		JP 2015523898 A	20 Aug 2015
		US 2012197388 A1	02 Aug 2012
		US 8845717 B2	30 Sep 2014
		US 2013023985 A1	24 Jan 2013
		US 8888843 B2	18 Nov 2014
		US 2015164637 A1	18 Jun 2015
		US 9592118 B2	14 Mar 2017
		US 2017245994 A1	31 Aug 2017
		WO 2012102928 A1	02 Aug 2012
		WO 2013192107 A1	27 Dec 2013
US 2014/0172070 A1	19 June 2014	US 2014172070 A1	19 Jun 2014
		US 9629716 B2	25 Apr 2017
		US 2012016464 A1	19 Jan 2012
		US 8657872 B2	25 Feb 2014
		US 2017224479 A1	10 Aug 2017
US 2008/0140190 A1	12 June 2008	US 2008140190 A1	12 Jun 2008
		AU 2002362441 A1	14 Apr 2003
		AU 2002362442 B2	07 Aug 2008
		AU 2003277115 A1	23 Apr 2004
		AU 2003277116 A1	23 Apr 2004
		AU 2003277118 A1	23 Apr 2004
		AU 2005244782 A1	01 Dec 2005
AU 2005275509 A1	23 Feb 2006		
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2009)			



INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		AU 2006230086 A1	05 Oct 2006
		AU 2006230087 A1	05 Oct 2006
		AU 2009208049 A1	27 Aug 2009
		CA 2455444 A1	10 Apr 2003
		CA 2462254 A1	10 Apr 2003
		CA 2498030 A1	15 Apr 2004
		CA 2563049 A1	01 Dec 2005
		CA 2573756 A1	23 Feb 2006
		CA 2601818 A1	05 Oct 2006
		CA 2602942 A1	05 Oct 2006
		CN 1610529 A	27 Apr 2005
		CN 1703176 A	30 Nov 2005
		CN 1988860 A	27 Jun 2007
		CN 101068508 A	07 Nov 2007
		CN 101108144 A	23 Jan 2008
		CN 101184454 A	21 May 2008
		CN 101184454 B	20 Oct 2010
		CN 101184455 A	21 May 2008
		EP 1434542 A2	07 Jul 2004
		EP 1434621 A2	07 Jul 2004
		EP 1562522 A2	17 Aug 2005
		EP 1562522 B1	31 Dec 2008
		EP 1748745 A2	07 Feb 2007
		EP 1748745 B1	23 Dec 2015
		EP 1788983 A2	30 May 2007
		EP 1865887 A1	19 Dec 2007
		EP 1865888 A1	19 Dec 2007
		HK 1073423 A1	02 Nov 2007
		HK 1082175 A1	31 Jul 2009
		JP 2005504577 A	17 Feb 2005
		JP 4458845 B2	28 Apr 2010
		JP 2006501033 A	12 Jan 2006
		JP 2007536989 A	20 Dec 2007
		JP 2008506494 A	06 Mar 2008
		JP 2008534084 A	28 Aug 2008
		JP 2008534085 A	28 Aug 2008
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 6893459 B1	17 May 2005
		US 2004138745 A1	15 Jul 2004
		US 7291168 B2	06 Nov 2007
		US 7305717 B1	11 Dec 2007
		US 2005010287 A1	13 Jan 2005
		US 7381220 B2	03 Jun 2008
		US 2004127981 A1	01 Jul 2004
		US 7527646 B2	05 May 2009
		US 2005222488 A1	06 Oct 2005
		US 7691144 B2	06 Apr 2010
		US 2005216079 A1	29 Sep 2005
		US 7887583 B2	15 Feb 2011
		US 2008065204 A1	13 Mar 2008
		US 8016882 B2	13 Sep 2011
		US 2009228099 A1	10 Sep 2009
		US 8142494 B2	27 Mar 2012
		US 2011015730 A1	20 Jan 2011
		US 8163013 B2	24 Apr 2012
		US 2010130992 A1	27 May 2010
		US 8187207 B2	29 May 2012
		US 2012232645 A1	13 Sep 2012
		US 8690858 B2	08 Apr 2014
		US 2004260393 A1	23 Dec 2004
		US 8784482 B2	22 Jul 2014
		US 2012209377 A1	16 Aug 2012
		US 8858622 B2	14 Oct 2014
		US 2005055089 A1	10 Mar 2005
		US 8956407 B2	17 Feb 2015
		US 2012035718 A1	09 Feb 2012
		US 8979925 B2	17 Mar 2015
		US 2011295059 A1	01 Dec 2011
		US 9179896 B2	10 Nov 2015
		US 2015182337 A1	02 Jul 2015
		US 9498331 B2	22 Nov 2016
		US 2015289976 A1	15 Oct 2015
		US 9597184 B2	21 Mar 2017
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2009)			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 2011319990 A1	29 Dec 2011
		US 9610161 B2	04 Apr 2017
		US 2004127982 A1	01 Jul 2004
		US 2004243107 A1	02 Dec 2004
		US 2005222489 A1	06 Oct 2005
		US 2005228422 A1	13 Oct 2005
		US 2006106278 A1	18 May 2006
		US 2006106279 A1	18 May 2006
		US 2006252984 A1	09 Nov 2006
		US 2008091059 A1	17 Apr 2008
		US 2008091264 A1	17 Apr 2008
		US 2008140188 A1	12 Jun 2008
		US 2009069885 A1	12 Mar 2009
		US 2009287179 A1	19 Nov 2009
		US 2009306622 A1	10 Dec 2009
		US 2009326648 A1	31 Dec 2009
		US 2010161044 A1	24 Jun 2010
		US 2011137411 A1	09 Jun 2011
		US 2011251684 A1	13 Oct 2011
		US 2012185040 A1	19 Jul 2012
		US 2014222138 A1	07 Aug 2014
		US 2015157459 A1	11 Jun 2015
		US 2016045308 A1	18 Feb 2016
		US 2016067043 A1	10 Mar 2016
		US 2016374812 A1	29 Dec 2016
		US 2017055969 A1	02 Mar 2017
		US 2017156864 A1	08 Jun 2017
		US 2017216031 A1	03 Aug 2017
		WO 03028558 A2	10 Apr 2003
		WO 03028802 A2	10 Apr 2003
		WO 2004030568 A2	15 Apr 2004
		WO 2004030569 A2	15 Apr 2004
		WO 2004030570 A2	15 Apr 2004
		WO 2005112827 A2	01 Dec 2005
		WO 2006019498 A2	23 Feb 2006
		WO 2006105008 A1	05 Oct 2006
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2009)			

INTERNATIONAL SEARCH REPORT Information on patent family members		International application No. <b>PCT/SG2017/050296</b>	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		WO 2006105009 A1	05 Oct 2006
		WO 2009038724 A1	26 Mar 2009
		WO 2009038725 A1	26 Mar 2009
		WO 2010033176 A1	25 Mar 2010
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. Form PCT/ISA/210 (Family Annex)(July 2009)			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 8016882 B2	13 September 2011	US 2008065204 A1	13 Mar 2008
		US 8016882 B2	13 Sep 2011
		AU 2002362441 A1	14 Apr 2003
		AU 2002362442 B2	07 Aug 2008
		AU 2003277115 A1	23 Apr 2004
		AU 2003277116 A1	23 Apr 2004
		AU 2003277118 A1	23 Apr 2004
		AU 2005244782 A1	01 Dec 2005
		AU 2005275509 A1	23 Feb 2006
		AU 2006230086 A1	05 Oct 2006
		AU 2006230087 A1	05 Oct 2006
		AU 2009208049 A1	27 Aug 2009
		CA 2455444 A1	10 Apr 2003
		CA 2462254 A1	10 Apr 2003
		CA 2498030 A1	15 Apr 2004
		CA 2563049 A1	01 Dec 2005
		CA 2573756 A1	23 Feb 2006
		CA 2601818 A1	05 Oct 2006
		CA 2602942 A1	05 Oct 2006
		CN 1610529 A	27 Apr 2005
		CN 1703176 A	30 Nov 2005
		CN 1988860 A	27 Jun 2007
		CN 101068508 A	07 Nov 2007
		CN 101108144 A	23 Jan 2008
		CN 101184454 A	21 May 2008
		CN 101184454 B	20 Oct 2010
		CN 101184455 A	21 May 2008
		EP 1434542 A2	07 Jul 2004
		EP 1434621 A2	07 Jul 2004
		EP 1562522 A2	17 Aug 2005
		EP 1562522 B1	31 Dec 2008
		EP 1748745 A2	07 Feb 2007
		EP 1748745 B1	23 Dec 2015
		EP 1788983 A2	30 May 2007
		EP 1865887 A1	19 Dec 2007
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2009)			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		EP 1865888 A1	19 Dec 2007
		HK 1073423 A1	02 Nov 2007
		HK 1082175 A1	31 Jul 2009
		JP 2005504577 A	17 Feb 2005
		JP 4458845 B2	28 Apr 2010
		JP 2006501033 A	12 Jan 2006
		JP 2007536989 A	20 Dec 2007
		JP 2008506494 A	06 Mar 2008
		JP 2008534084 A	28 Aug 2008
		JP 2008534085 A	28 Aug 2008
		US 6893459 B1	17 May 2005
		US 2004138745 A1	15 Jul 2004
		US 7291168 B2	06 Nov 2007
		US 7305717 B1	11 Dec 2007
		US 2005010287 A1	13 Jan 2005
		US 7381220 B2	03 Jun 2008
		US 2004127981 A1	01 Jul 2004
		US 7527646 B2	05 May 2009
		US 2005222488 A1	06 Oct 2005
		US 7691144 B2	06 Apr 2010
		US 2005216079 A1	29 Sep 2005
		US 7887583 B2	15 Feb 2011
		US 2009228099 A1	10 Sep 2009
		US 8142494 B2	27 Mar 2012
		US 2011015730 A1	20 Jan 2011
		US 8163013 B2	24 Apr 2012
		US 2010130992 A1	27 May 2010
		US 8187207 B2	29 May 2012
		US 2012232645 A1	13 Sep 2012
		US 8690858 B2	08 Apr 2014
		US 2004260393 A1	23 Dec 2004
		US 8784482 B2	22 Jul 2014
		US 2012209377 A1	16 Aug 2012
		US 8858622 B2	14 Oct 2014
		US 2005055089 A1	10 Mar 2005
		US 8956407 B2	17 Feb 2015
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2009)			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 2012035718 A1	09 Feb 2012
		US 8979925 B2	17 Mar 2015
		US 2011295059 A1	01 Dec 2011
		US 9179896 B2	10 Nov 2015
		US 2015182337 A1	02 Jul 2015
		US 9498331 B2	22 Nov 2016
		US 2015289976 A1	15 Oct 2015
		US 9597184 B2	21 Mar 2017
		US 2011319990 A1	29 Dec 2011
		US 9610161 B2	04 Apr 2017
		US 2004127982 A1	01 Jul 2004
		US 2004243107 A1	02 Dec 2004
		US 2005222489 A1	06 Oct 2005
		US 2005228422 A1	13 Oct 2005
		US 2006106278 A1	18 May 2006
		US 2006106279 A1	18 May 2006
		US 2006252984 A1	09 Nov 2006
		US 2008091059 A1	17 Apr 2008
		US 2008091264 A1	17 Apr 2008
		US 2008140188 A1	12 Jun 2008
		US 2008140190 A1	12 Jun 2008
		US 2009069885 A1	12 Mar 2009
		US 2009287179 A1	19 Nov 2009
		US 2009306622 A1	10 Dec 2009
		US 2009326648 A1	31 Dec 2009
		US 2010161044 A1	24 Jun 2010
		US 2011137411 A1	09 Jun 2011
		US 2011251684 A1	13 Oct 2011
		US 2012185040 A1	19 Jul 2012
		US 2014222138 A1	07 Aug 2014
		US 2015157459 A1	11 Jun 2015
		US 2016045308 A1	18 Feb 2016
		US 2016067043 A1	10 Mar 2016
		US 2016374812 A1	29 Dec 2016
		US 2017055969 A1	02 Mar 2017
		US 2017156864 A1	08 Jun 2017
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 2017216031 A1	03 Aug 2017
		WO 03028558 A2	10 Apr 2003
		WO 03028802 A2	10 Apr 2003
		WO 2004030568 A2	15 Apr 2004
		WO 2004030569 A2	15 Apr 2004
		WO 2004030570 A2	15 Apr 2004
		WO 2005112827 A2	01 Dec 2005
		WO 2006019498 A2	23 Feb 2006
		WO 2006105008 A1	05 Oct 2006
		WO 2006105009 A1	05 Oct 2006
		WO 2009038724 A1	26 Mar 2009
		WO 2009038725 A1	26 Mar 2009
		WO 2010033176 A1	25 Mar 2010
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			



INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2017/050296	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
US 4994077 A	19 February 1991	US 4994077 A	19 Feb 1991
US 7972378 B2	05 July 2011	US 2009287299 A1	19 Nov 2009
		US 7972378 B2	05 Jul 2011
		AU 2009206672 A1	30 Jul 2009
		AU 2009206672 B2	12 Jun 2014
		CA 2714062 A1	30 Jul 2009
		CN 101980670 A	23 Feb 2011
		CN 101980670 B	23 Apr 2014
		EP 2254512 A1	01 Dec 2010
		EP 2254512 B1	06 Jan 2016
		EP 2254513 A1	01 Dec 2010
		EP 2254513 B1	28 Oct 2015
		EP 2254514 A2	01 Dec 2010
		EP 2254515 A1	01 Dec 2010
		EP 2254515 B1	07 Jan 2015
		JP 2011509806 A	31 Mar 2011
		JP 5628688 B2	19 Nov 2014
		JP 2011509805 A	31 Mar 2011
		JP 5687070 B2	18 Mar 2015
		MX 2010008171 A	07 Dec 2010
		US 2009192585 A1	30 Jul 2009
		US 8157852 B2	17 Apr 2012
		US 2009198316 A1	06 Aug 2009
		US 8157853 B2	17 Apr 2012
		US 2009292350 A1	26 Nov 2009
		US 8628566 B2	14 Jan 2014
		US 2011224780 A1	15 Sep 2011
		US 8673000 B2	18 Mar 2014
		US 2012197379 A1	02 Aug 2012
		US 8685077 B2	01 Apr 2014
		US 2009192591 A1	30 Jul 2009
		US 9089422 B2	28 Jul 2015
		US 2009192586 A1	30 Jul 2009
		US 9149358 B2	06 Oct 2015
		US 2014081383 A1	20 Mar 2014
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			

INTERNATIONAL SEARCH REPORT		International application No.			
Information on patent family members		PCT/SG2017/050296			
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.					
Patent Document/s Cited in Search Report		Patent Family Member/s			
Publication Number	Publication Date	Publication Number	Publication Date		
		US 9333100 B2	10 May 2016		
		US 2014142694 A1	22 May 2014		
		US 9339382 B2	17 May 2016		
		US 2009254165 A1	08 Oct 2009		
		US 9393115 B2	19 Jul 2016		
		US 2009287290 A1	19 Nov 2009		
		US 2014142680 A1	22 May 2014		
		US 2016296327 A1	13 Oct 2016		
		US 2016296328 A1	13 Oct 2016		
		US 2016361184 A1	15 Dec 2016		
		WO 2009094188 A2	30 Jul 2009		
		WO 2009094189 A1	30 Jul 2009		
		WO 2009094197 A1	30 Jul 2009		
		WO 2009094501 A1	30 Jul 2009		
		US 2009/0043381 A1	12 February 2009	US 2009043381 A1	12 Feb 2009
				WO 2006041877 A2	20 Apr 2006
US 2005/0038470 A1	17 February 2005	US 2005038470 A1	17 Feb 2005		
		US 7735493 B2	15 Jun 2010		
		EP 1659988 A2	31 May 2006		
		EP 1659988 B1	17 Feb 2010		
		WO 2005016189 A2	24 Feb 2005		
End of Annex					
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.					